initi coverag
left asthma upsid initi overweight
invest summari initi coverag overweight
rate price target antibodi platform compani focus
inflamm immunolog condit lead asset etokimab
phase allerg condit atop dermat asthma
still unmet need success think etokimab sale may
peak vs anab current market cap also think compani
second wholli own clinic asset underappreci add key
piec option stori asset key clinic catalyst next
month think pivot clinic develop year
expect data vs etokimab patient current report
explain bullish ahead clinic readout program
near-term stock focu etokimab asthma data
confid ahead readout think share could trade
share trial placebo-control studi patient
benefit measur respiratori function key focu base analysi
earlier dupix data think singl dose etokimab could show
benefit placebo would compar earli dupix data
regeneron cover limit comparison singl
dose think etokimab efficaci deepen multi-dos expect
share highli volatil around readout character
think most-lik risk/reward rang share could trade high
share upsid low downsid
regardless asthma outcom think investor attent turn
next program current clinic asthma readout
think could opportun
inhibitor clinic two rare form psoriasi gener pustular
psoriasi gpp palmoplantar pustulosi ppp compani went clinic
earli gpp top-lin data expect conduct
extens check pathway gpp ppp convict
program proof concept achiev gpp think investor
assign credit ppp phase data see bigger
valuat risk price target overweight rate base
probabl adjust dcf risk includ lack efficaci etokimab asthma
atop dermat lack efficaci gpp ppp unexpect
disclosur section may found page
platform technolog multipl clinic stage
asset key catalyst horizon
call mani reason believ see mani clinic
success platform think current level leav room
meaning upsid clinic asset valid
compani overview clinic stage platform compani multipl clinic stage
asset lead asset etokimab studi mani allerg condit among
anab asset etokimab furthest ahead atop dermat early-stag data
octob sent share think meaning de-risk left
etokimab see multipl clinic catalyst next month key valu driver addit
clinic asset notabl add key piec diversif initi readout expect
believ underappreci
clinic stage platform technolog compani multipl clinic stage
asset compani platform technolog util human bodi endogen antibodi
creation mechan creat larger number potent antibodi therapeut target
earli valid platform seen etokimab atop dermat well
sever immuno-oncolog asset anapti licens tesaro tsro
cover includ clinic studi
compani lead asset etokimab studi mani allerg
indic etokimab target implic across mani allerg condit
asset studi atop dermat skin diseas similar eczema asthma
chronic sinus nasal polyp think strong scientif clinic valid
suggest could strong activ indic
among anab asset etokimab furthest ahead atop dermat
seen earli proof activ phase compani move etokimab
success think etokimab could achiev sale ad asthma think lead asset etokimab succes allerg diseasesif success think could sell gpp ppp think underappreci key upsid driverbi ye patient data etokimab patient vs current multipl etokimab readout next month give potenti meaning de-riskinginiti gpp data give us sens efficaci pathway think ppp remain unmet attract market opportunityw think opportun come focu broader macro trend see play timesupport view potenti target think atop dermat asthma underappreci market etokimab asthma data etokimab ad gpp data ppp datakey catalyst
phase trial diseas etokimab demonstr activ phase trial
atop dermat form eczema patient patient receiv one dose
etokimab show meaning clinic improv vs baselin core investor
pushback singl arm placebo studi also allow rescu topic
steroid perhap make earli draw conclus compani move etokimab
larger phase trial help answer question drug
addit pipelin asset continu move forward think add import
point diversif stori next month specif move
inhibitor clinic two rare skin diseas patient data
expect think asset underappreci think could repres
anoth meaning commerci opportun
exhibit overview portfolio
think target diseas area could grow major therapeut
categori time
atop dermat allerg asthma chronic sinus nasal polyp therapeut
option patient mani diseas immunolog psoriasi rheumatoid arthriti ra
fairli crowd therapeut option note anti-tumor necrosi factor tnf
deriv larg portion sale ra psoriasi sale approxim
addit indic like atop dermat allerg asthma similar preval rate
diseas sever far-few biolog approv comparison creat
attract opportun address unmet need accord check immunolog
key view payer creat competit due amount therapeut categori like
ra psoriasi
key part thesi given think etokimab could sale
categori success studi high-growth indic unmet need
anab etokimab
rel categori
rheumatoid arthriti
diseas area
 us indic popul vs number approv origin biolog target us patient popul sizeapprov origin biolog
think clinic catalyst single-most import stock driver
share next month
think single-most import stock driver clinic readout portfolio
exhibit catalyst view stock impact
compani data cantor fitzgerald research
even though think consider think key stock focu
clinic success platform even see posit readout competitor
abbvi cover upadacitinib regeneron cover
think import focu stock level market cap vs potenti peak
sale etokimab whether asset work technolog platform becom
exhibit cantor view stock driver month
compani data cantor fitzgerald research
clinic data updatesetokimab atop dermat dataetokimab asthma ppp gpp dataetokimab crswnp datacompetitor dataoth inhibitor data updat ad phase data updacitinib phase data crswnp new indic discuss target checkpoint agonist conditionsi commerci dynamicsdupix launch atop dermat asthma upadacitinib ra file safeti develop high dose get approv drugindicationcatalystwhenstock top-line rhinosinus w/nasal polypsiniti phase eclips trialyear end pustulosi ppp initi phase pustular psoriasi gpp gallop phase top-line dataearli dermatitisatla phase top-line pustulosi ppp phase top-line rhinosinus w/nasal polypseclips phase upcom catalyst august
think underappreci asset could
major driver share
report conduct detail analysi think next
product receiv investor focu stori
report discuss opportun could indic gpp ppp
think import data expect import consid
stock behav readout asthma asthma readout regardless outcom
think investor pivot evalu
inhibitor clinic develop rare dermatolog skin condit
think asset underappreci investor could import upsid driver
clinic data releas
exhibit background indic gpp ppp
compani data cantor fitzgerald research
ppp could blockbust opportun data expect review
literatur think ppp palmoplatar pustulosi could meaning market
opportun larg number patient exist biolog
littl impact diseas actual remind us atop dermat
gpp data expect could first commerci indic
launch think genet valid efficaci gpp
gener pustular psoriasi strong gpp sever diseas see
path market success although think market opportun gpp rel
small think success could turn investor attent ppp gpp serv initi
proof concept
see ppp larger opportun think gpp gateway investor
begin assign credit ppp view larger long-term market opportun
two diseas similar underli patholog think initi data gpp
help investor becom comfort ppp market opportun
gpppppdiseasegener pustular psoriasispalmoplantar pustulosisu bodi multi-organ inflammatori condit fatalharden pustul hand feet signific impact qualiti lifecurr treatmentscantor forecast label cyclosporin retinoid biolog noth approv specif either diseas rare diseas price approv ppp assum price would much lower ppp would main sourc revenu august
probabl success gpp ppp would worth
base dcf
think investor current assign littl credit program thu see favor
risk-reward ahead initi clinic data readout gpp ppp indic
term core valuat compani lot
confid lead asset etokimab continu drive valu
mani etokimab readout horizon could serv major inflect point stori
current data etokimab earli small number key point
investor pushback stori howev think get data etokimab
could major inflect point stori
next month expect multipl readout etokimab allerg diseas much
larger patient number think readout serv key de-risk point asset
key driver either posit neg stock perform
exhibit view etokimab viabl target
compani data cantor fitzgerald research
upcom asthma data key near-term stock focu
good data look benefit placebo mid-to-high singl
think investor look liter improv versu baselin
think most-relev clinic comparison phase dupix data wenzel
show dupix benefit placebo high eosinophil patient
reason think work asthma
proof concept dupix inhibitor asthma
inhibit individu shown efficaci target
improv eosinophil asthma
extens literatur demonstr key role asthma
hit clinic proven target etokimab inhibit think also inhibit clinic proven allerg target multipl commerci drug activ earli data earli phase data atop dermat even peanut allergi demonstr activ allerg scienfic research target extens scientif literatur document role play allerg pharma player seem agre target alon identifi promis target think good thing share ahead data summari reason think etokimab readout could success august
mani clinic preclin model shown key sustain asthmat
respons allergen instanc loss function mutat shown
offer protect asthma
activ atop dermat diseas similar underli
mechan eosinophil asthma
clinic activ atop dermat anoth allerg eosinophil condit
show activ eosinophil allerg diseas mani patient
atop dermat also asthma vice versa underli immun irregular
often
activ reduc asthmat exacerb phase peanut allergi
although data peanut allergi overli compel oral food
challeng opinion benefit seen asthma symptom patient
treat specif dose patient concomit allergi
symptom rhiniti pruritu uticaria asthma flare nut allergi vs
larg pharma move inhibitor forward asthma stealth mode
could suggest earli clinic activ seen intern earli stage
studi compani instanc roch cover move patient
phase asthma move patient asthma studi
success think etokimab could sale
could sale
base case probabl adjust base clinic progress sale
estim
unadjust sale estim success indic close
base case adjust revenu indic includ estim
exhibit unadjust sale successfulsourc cantor fitzgerald base case sale estim base case sale estim etokimabsourc cantor fitzgerald researchsourc cantor fitzgerald august
valuat see upsid clinic readout next
assign credit etokimab atop dermat asthma
ppp gpp respect
think two most-import stock driver anab share next month
understand etokimab clinic profil
earli data clinic stage asset
exhibit overview cantor base valuat
exhibit overview cantor base valuat assumpt
probabl success unadjust sale adjust atop market peanut sale sale multipl cantor equiti research year launch august
pictur see positive/risk reward mani clinic catalyst
current cash tesaro royalti worth valuat
exhibit variou risk/reward scenario base model analysi
includ rang scenario includ valuat model analysi
exhibit variou risk/reward scenario base model analysi
includ scenario analysi clinic probabl success asthma
atop dermat fair valuat output model
pricebear basebul avaluationcantor take potenti stock scenariosscenariovalu upside/downsidewhat happensbear complet failuresbear etokimab efficaci limit efficaci data credit etokimab limit credit etokimab discontinu investor give credit base probabl adjust credit etokimab increas success etokimab chang assumptionsbul increas success etokimab ppp gppbull use peak sale multipl peak probabl adj sale
upside/downsideneg asthma stock herecantor ad/asthma assumptionsposit asthma dermat po asthma po
risk pushback overview stock debat
lot controversi surround name etokimab work think
lead meaning upsid current level
summar key stock debat stand key topic focu whether clinic
program asthma atop dermat work valid data seen far
discuss point includ debat whether larg market whether anab
etokimab even success get overshadow drug larger commerci player
stock debatebackgroundbear say bull say cantor thoughtsasthma data work activ placebo singl dose etokimabw think investor look benefit placebolimit clinic data etokimab make hard inhibit mani target alon know work asthma could even activ would surpris etokimab show least activ asthma think like activ target asthma etokimab success inhibit think key risk small size trial atop dermat data hold larger trial phase trial patient enrol data guid data small sampl size placebo controlrescu topic steroid inhibit target know work data singl dose competit multipl dose data highli durablew think multipl dose increas efficaci product vs seen singl dose even placebo respons impact steroid think effect multipl dose lead competit efficaci market size larg ad asthma market dermatologist like use biologics/ad sever diseas asthma crowd marketsimilar preval indic ra psoriasi larg biolog market think ad asthma grow becom larg brand market chronic indic sever impact qualiti life similar preval larg space competit ad/asthma market crowd ad asthma crowd market compet much larger compani oral inhibitor developmentrel number product ra psoriasi competit smallsafeti jak inhibitor concernoth target receptor cytokinew think mani player help grow overal market size also cautiou jak inhibitor safeti infect vte ad stock perspect think import focu proof efficaci etokimab valid platform sourc compani data cantor research august
stock debat near-term data readout asthma think
could lead upsid depend data qualiti
downsid think share could trade low weak data thu
flag risk/reward balanc slightli neg event program complet
failur doomsday scenario safeti event think share could trade low
think unlik scenario
major anab market cap current attribut etokimab
asthma trial show bad outcom sign activ think could
signific downsid risk hand etokimab shown work asthma think
investor posit view atop dermat data
basic asthma data asthma key read entir platform
would thu expect share highli volatil around event
read atop dermat given limit data atop dermat program to-
date posit neg read asthma program could make investor feel either
lot lot less comfort atop dermat program note
asthma studi placebo control wherea atop dermat data read
to-dat
similar diseas key market opportun two diseas similar underli
allerg caus overlap patient popul thu think investor would look
likelihood success phase atop dermat data size
etokimab market opportun asthma data neg
exhibit scenario analysi upcom asthma data
think
downsid
base
think
could see
data
compani cash per share estim tesaro tsro cover
royalti npv basi worth thu estim worst-cas scenario
stock would worth
outputetokimab inputprob adj etokimab salesdcf upside/downsidesup bull casehighli posit data much better benefit vs success asthma atop caseposit asthma data compar benefit vs success etokimab po bear caseweak efficaci show benefit vs po etokimab bear casei discontinu entir etokimab programno effect safeti tsro cantor equiti researchcurr market pricescenario august
stock debat atop dermat data hold
despit limit data think earli data show strong signal singl
dose expect efficaci increas multipl dose
overal think phase data although small number show depth durabl
respons would highli unlik ineffect molecul also think
multipl dose etokimab longer studi deepen effect instanc saw
dupix depth respons deepen sustain dose inhibit
similar mechan think could similar effect etokimab
exhibit thought atop dermat data
bear case data bull responsecantor atop dermat phase patient trial placebo control small patient set might high placebo response-th respons rate much higher seen placebo arm atop dermat trial seen data -patient receiv dose placebo day saw minim respons dose day sever patient popul vs ad trial placebo effect could lower vs ad studi -durabl respons day would also inconsist placebo responsew think could placebo effect seen patient overal phase ad data despit small number show efficaci highli refractori patient popul would unlik seen inact drug rescu steroid allow atop dermat phase trial could led respons seen trial-top steroid oral allow small amount exact amount protocol disclos patient allow rescu usag nonrespond could use steroid hit thu steroid could technic contribut response-manag said bump easi score seen result steroid usage- think unlik steroid impact result think indic activ rule possibl steroid usag led improv averag easi reduct rate although inclin think impact small trial could enrol right patient -becaus patient popul sever lower probabl trial enrol right patient super respond think risk data hold larger patient number think like scenario simpli respons rate would high confid activ drug upstream work complimentari way cytokin believ studi dupix combin mani scientif public document fact inhibit also lower level think could signal mechan activ outsid key risk etokimab long term howev look literatur speak basic scienc immunologist think inhibit could enough lead clinic meaning result epeci light literatur show predomin pathway lead sustain vs transient immun reaction august
stock debat longer term think market opportun
target key area growth therapeut space
think allerg diseas one anapti studi could next commerci
frontier space
 inflamm immunolog space biotech largest-sel drug includ
abbv humira amgn enbrel wherea chronic inflammatori diseas
arthriti dozen approv biolog includ drug humira
enbrel chronic inflammatori diseas atop dermat allerg asthma chronic
sinus far-few approv biolog think diseas repres major growth
opportun novel therapeut consid prior biolog shown limit efficaci
treat diseas
exhibit immunolog popul vs number approv drug
studi atop
derm asthma
rel categori
arthriti diseas
area
compani data cantor fitzgerald research
anti-tnf tumor necrosi factor inhibitor class sale global see mani
similar anti-tnf market allerg condit studi
look size anti-tnf inhibitor class earn signific portion sale
rheumatoid arthriti ra psoriasi see mani similar atop dermat
allerg asthma space chronic inflammatori condit larg preval
larg impact patient qualiti life atop dermat allerg asthma similar patient
preval ra psoriasi far-few approv biolog
biolog reach penetr atop dermat ra estim
atop dermat would market global
although assum base case think interest sensit
think growth potenti atop dermat biolog reach penetr ad similar
alreadi achiev ra sensit support view mani player ad long
term may help grow usag biolog may expand overal size market
sensit assum biolog may penetr patient popul treat moderate-to-
sever ad treat ra patient receiv biolog figur roch
cover diagnos ra treat therapi biolog
 us indic popul vs number approv origin biolog target us patient popul sizeapprov origin biolog
non-biolog contrast sensit calcul assum ad
diagnos patient us treat vs ra account fact
mild patient ad might go without treatment
exhibit anti-tnf market associ sale
us diagnos ra patient treat biolog
roch publish estim diagnos ra patient us
treat treat biolog suggest us
diagnos ra treat biolog treat ra treat
contrast base case model diagnos ad patient
treat biolog jak still much lower vs ra market
atop dermat estim patient us treat moderate-to-
sever condit model ad patient us treat biolog
jak inhibitor penetr rate total number diagnos ad patient
although think treatment paradigm allerg condit includ biolog may take
time evolv think signific area growth biolog long
current pushback physician treat atop dermat allerg asthma
comfort biolog heard doctor check well howev think
paradigm evolv chang time physician increas experi
agent compar biolog mani current treatment allerg diseas
 steroid cyclosporin think clear medic rational efficaci
safeti perspect greater biolog usag diseas
base case model assumpt atop dermat space penetr
although view ad market probabl much-mor bullish note still
model significantli fewer ad patient ra patient treat biolog
exhibit cantor biolog penetr patient number forecast atop dermat
note ra assumpt approxim assum minim penetr growth
illustr purpos compar ra vs ad
exhibit cantor take us atop dermat market size
 penetr diagnos patientsu biolog treat patientsu ad biolog treatedu ra biolog treat thousand us ra biolog penetr diagnos us ad biolog penetr market shareu annual ad market sale us atop dermat salestot ad us biolog sale player us ad sale probabl adjust us market share august
stock debat think competit updat
major driver share level
howev bear case atop dermat asthma crowd market
mani novel agent develop agent similar mechan action
also target show exhibit louis chen
cover lilli louis chen cover
overal think larg market room mani player mani competitor
program compon efficaci safeti could inhibit approvability/commerci
uptak establish clinic efficaci asset could strong strateg addit
portfolio player market
exhibit overview commerci debat
jak inhibitorsoth inhibitorssummarythes oral product develop atop dermat well ra lly/inci jak inhibitor phase atop dermat sever player regn/sni gsk inhibitor developmentpotenti headwind inhibitor breakthrough design ad-fast act short time efficacy- especi establish player space could bundl jak product deal w/payers-if equival efficacy/toler etokimab class could evolv mani asset view similarli doctor larger player could advantagepotenti tailwind safeti concern concern vte clot infect risk could limit uptak and/or prevent regulatori approv doses- commerci dermatologist could sensit infect rates-th inhibitor develop target receptor cytokin etokimab could limit efficaci and/or tolerabilitypotenti updat jak safeti upadacitinib file ra mid color file phase atop dermat data potenti asthma phase data trial complet enrol april august
think competit updat could greatest impact share
roch cover regeneron cover glaxosmithklin
gsk cover inhibitor
regn/sni asthma phase trial inhibitor compani
said littl seen clinic preclin asset
think possibl updat either program releas base
timelin outlin clinicaltri gov specif accord clinicaltri gov
inihibitor complet enrol asthma phase trial april
could put data disclosed/pres regn phase asthma trial combin
w/dupix clinicaltri gov estim primari complet date septemb
trial still enrol
stock perspect think downsid upsid ahead
competit data updat especi competitor larg compani may
disclos data posit
present key competit updat watch mani
sure compani top-lin even disclos data trial
phase trial
outsid trial think pfizer could first phase
atop dermat readout jade mono wich clinicaltri gov primari complet date
often inaccur march trial began enrol late
think could upsid share fda review upadacitib ra reveal
regulatori concern safeti asset
think abbv upadacitinib well pfe view key competitor
ad space discuss chart thu safeti concern aris regulatori perspect
 potenti adcom part label think could view favor
investor biolog ad space dupix etokimab
exhibit summari competitor program clinic potenti upcom updat
mani competitor atop dermat space hightlight program
watch close
exhibit summari atop dermat program clinic
drugcompanystag admoacommentsdupilimab design adupadacitinibabbvphas inhibitorbreakthrough design adbaricitinib olimi lly/incyphas inhibitorbreakthrough design adamg ep callcompetit landscap moder sever atop dermat ad assetcompanytargetprogramwhatestim ad program- dose first patient juli patient trialtoplin phase ad data late depend enrol randa file ra expect detail safeti commerci potenti approv process/labelingmid color safeti ad program dose first patient decemb current enrol multipl phase trial potenti top-line ad data primari complet ct gov march jade mono studyamg subq asthma phase complet enrol april primari endpoint weeks- phase asthma data- disclos asthma program combo w/dupi- current enrol first patient dose march studi everi week subq asthma vs dupix monotherapi dupix combin potenti asthma phase data- clinicaltri gov list sep estim primari complet iv asthma phase current enrol began enrol april primari endpoint mid disclos data clinicaltri gov list feb estim primari complet date
show competitor asthma well mani market alreadi unmet need remain
exhibit asthma therapi market pipelin
drugcompanytargetstatu asthmaadministrationxolair omalizumab rocheigeapprov everi weeksblack box anaphylaxisnucala everi week must reconstitut administ healthcar professionalcinqair everi week infus minutesblack box anaphylaxisfasenra everi week dupix pdufa octob everi weekstezepelumabamgn/azntslpphas ongoingsubq everi receptor phase ongoingmonthli cytokin phase ongoingmonthli receptor phase ongoingeveri week receptor phase ongoingmonthli ivsourc compani data august
inhibitor list descript full catalyst chart
includ detail around inhibitor key program develop
exhibit inhibitor develop
also includ key catalyst space focus
exhibit catalyst watch month
moleculecompanyreceptor/cytokinedevelop stagestatusestim on-going atop dermatitisphas on-going asthmaasthma phase top-line phase top-line subq asthma phase complet enrol april primari endpoint week mid phase asthma data studi copd phase week subq asthma phase vs dupix monotherapi dupix combin list sep estim primari complet datealso studi copd phase iv asthma phase began enrol april primari endpoint mid list feb estim primari complet datealso studi allerg fungal airway diseas began recruit april ep call phase start data disclosedroch asthma trial asthma trial inhibitor develop awar cantor fitzgerald research compani data mid list feb estim primari complet dateamg enrol april week recruit clinicaltri gov list sep estim primari complet dermatitisphas co guidanc august
technolog use human immun system make
antibodi gener technolog use endogen human
process creat antigen enabl compani creat antibodi diseas target
hard effect neutral antibodi gener method
despit mani commerci therapeut antibodi still limit
exist antibodi platform abl accomplish
antibodi natur occur product bodi immun system
bodi white blood cell produc varieti antibodi order protect bodi
pathogen harm bacteria antibodi bind target antigen attempt
antibodi neutral target antibodi also manufactur treat diseas
target becom major class drug
first manufactur antibodi therapeut purpos approv
sinc time field therapeut antibodi grown dramat modal
howev still limit current antibodi technolog abl
despit advanc antibodi select engin mani target remain difficult
neutral variou antibodi technolog base mous yeast model creat
antibodi certain target low potenc limit function activ bind
wrong part target difficult manufactur
see room new antibodi develop platform target
platform unabl
despit larg number approv antibodi think still room improv
antibodi platform technolog target next wave diseas previous
hard dose therapeut
technolog util human bodi intern antibodi gener
process identifi potent antibodi tradit hard-to-target antigen
contrast therapeut antibodi gener use mous model
human bodi endogen abil creat antibodi varieti harm
order adapt varieti immun challeng human bodi endogen
process call somat hypermut shm order creat antibodi need
particular immun threat enabl bodi respond pathogen ad-hoc basi
depend specif pathogen
anaptyss technolog identifi enzym induc human antibodi
format vitro cell system
specif technolog use enzym activation-induc cytidin deaminas
aid natur activ human bodi encount pathogen
need build antibodi although vivo human usag technolog
unabl creat antibodi use aid enzym initi shm somat
hypermut mammalian cell system
exhibit overview somat hypermut vitro process
antibodi gener model limit divers potenc antibodi
creat
anoth process antibodi creation inject mous antigen desir
target neutral replic result antibodi mous produc
although produc mani effect antibodi therapeut mouse-gener
antibodi alway translat effect target neutral human mous
immun system respond antigen time antibodi gener often
effect neutral given target human gener antibodi might
use human immun system abl gener antibodi
specif anab technolog abl gener wide varieti antibodi use
human shm somat hypermut process human shm antibodi product
process typic produc mani antibodi vs model mous give
larg select antibodi given target choos tri find
potent antibodi bring clinic
anaptyss technolog alreadi gener mani clinic stage asset think
asset licens tesaro tsro cover
import point de-risk platform
partnership tesaro seen anab platform technolog
abl success gener antibodi sever immune-oncolog target
alreadi seen initi proof-of-concept data
demonstr extend interv vs market therapi
tesaro plan file bla msi-high tumor think readout
data esmo bla file serv import point
valid compani platform product head toward commerci
addit dose regimen everi week vs everi week keytruda
opdivo also demonstr potenc anab antibodi technolog creat longer-
although anab econom rel minor asset licens tsro mid-to-high
single-digit royalti view asset import piec valid platform
exhibit tesaro oncolog antibodi partnership
longer term think anab technolog continu gener varieti
clinic candid help diversifi stori
near-term target view checkpoint agonist auto-
although near term investor may most-focus data compani lead asset
etokimab think import aspect stori technolog
gener mani addit clinic candid well
next accord manag
compani interest checkpoint inhibitor agonist autoimmun diseas
checkpoint inhibitor turn bodi immun respons thu
use inhibit cancer tumor turn bodi immun respons
tumor signal checkpoint inhibitor
understand checkpoint agonist hard formul anab
technolog could abl
wherea checkpoint inhibitor inhibit order increas immun
respons cancer program clinic celgen cover
preclin wholli own stage focu checkpoint agon decreas
immun respons auto-immun diseas accord compani cell cell
suppress modul checkpoint inhibitor could implic across number
compani guid anoth candid move clinic
suspect agonist auto-immun diseas differ one
clinic develop celgen non-exclus collabor
explor compani technolog also saw issu patent
antibodi target ngf activin receptor type ii
know mean clinic candid think illustr
target although sure compani use antibodi technolog
could
compani mention
checkpoint agon next
oncolog seen
agon ulcer coliti
instanc gsk guid poc
data uc
targetpat receptor type iibold asset clinic stage assetssourc googl patent august
upcom asthma data key near-term stock
reason think work asthma
proof concept dupix inhibitor asthma
inhibit individu shown efficaci target
improv eosinophil asthma
extens literatur demonstr key role asthma
mani clinic preclin model shown key sustain asthmat
respons allergen instanc loss function mutat shown
offer protect asthma
activ atop dermat diseas underli
mechan similar eosinophil asthma
clinic activ atop dermat anoth allerg eosinophil condit
show activ eosinophil allerg diseas mani patient
atop dermat also asthma vice versa underli immun irregular
often
activ reduc asthmat exacerb phase peanut allergi
although data peanut allergi overli compel oral food
challeng opinion benefit seen asthma symptom patient treat
specif patient concomit allerg symptom
rhiniti pruritu uticaria asthma flare nut allergi vs placebo
larg pharma move inhibitor forward asthma stealth mode
could suggest earli clinic activ seen intern earli stage
studi compani instanc roch move phase studi
asthma move asthma studi inhibitor
good data look benefit placebo
think investor look liter improv vs placebo
think most-relev clinic comparison phase dupix data wenzel
show dupix benefit placebo high eosinophil patient
asthma phase single-dos placebo-control trial high eosinophil
first patient data get inhibitor asthma thu view
import proof concept mechan asthma atop dermat phase data
placebo arm pushback dataset trial singl dose
placebo given high eosinophil patient alreadi background steroid
long-act beta agonist
investor like make read atop dermat asthma data make
import readout stock
think current make major anab stock valuat eye
investor success asthma think help valid program
atop dermat well show role allerg diseas hand
unsuccess asthma think could creat investor doubt atop
exhibit phase asthma studi design
cantor fitzgerald research clinicaltri gov compani data
amount air blown one second measur volum liter
percent predict
forc expiratori volum one second result test includ
actual volum liter patient abl exhal one second percent predict
patient compar percentag basi healthi patient similar
demograph age sex height etc would predict key clinic measur
earli stage asthma studi indic lung function earli get read
impact rate exacerb
think most-import comparison asthma data earli
dupix data base dupix experi earlier studi think volum
percentag increas vs placebo view clinic meaning singl dose
dupix similar mechan action downstream
dupix closest commerci competitor make comparison
phase wenzel dupix show benefit vs placebo
phase studi high eosinophil patient dose dupix background steroid
laba similar phase patient specif dose
patient show increas volum basi
approxim four week dupix arm increas
placebo arm show increas thu dose dupix patient experienc
percentag increas approxim patient cohort make
rel sizabl studi
placebo activeregimensingl dose iv steroid labaplacebo steroid labaobersv timeframew estim initi top-line data might week longer term follow medic meetingsexpect compani phase asthma trial designsourc compani data cantor fitzgerald research
exhibit data phase dupix studi
key data point
compar
dose high eosinophil
 percentag
increas vs placebo
 percentag
increas
benefit vs placebo
dupix phase
anoth comparison dupix data wherein dupix show benefit
vs placebo one-to-four week dose
phase wenzel dupix also studi high eosinophil asthma patient
percentag increas directli report far find howev increas
 baselin baselin report think possibl look
addit data point although caveat math vs math
investig compani
phase dupix show increas vs placebo dose
phase dupix show improv liter high eosinophil patient
vs baselin singl dose liter month dose vs
placebo increas respect
specif singl dose dupix patient phase mean
increas volum liter vs baselin capac liter
equat increas volum four week four dose dupix
patient phase increas capac increas vs
baselin liter also look compar placebo respons
two studi ensur compar
exhibit chang baselin cantor estim
note phase studi dupix dose weekli phase
dupix dose arm everi two week everi two week
lower dose use phase studi
similar phase studi patient dupix phase studi
background long-act beta agonist laba background steroid
although effect taper laba steroid studi four week
dupix phase studi think first four week studi repres good
comparison evalu phase data
refer provid data dupix phase supplementari appendix
use calcul percentag chang
exhibit back-up calcul
supplement wenzel ford pearlman et al dupilumab persist asthma elev eosinophil
dupilumab weekli laba high dose inhal steroidsplacebo laba high dose inhal steroidsbaselin chang baelineweek singl dose chang baselin cantor week chang baselin cantor week chang baselin cantor week chang baselin cantor sourc wenzel cantor fitzgerald researchmean chang liter report wenzel chang baselin calcul mean chang baselin august
anoth measur percent predict
specif measur patient capac percentag would
predict healthi person compar characterist age sex height
dupix led increas approxim percentag point one dose
report baselin dupix placebo arm one week
one dose dupix appear around dupix arm
increas slightli placebo arm four week appear
increas dupix vs rel stabl placebo arm
overal patient popul high low eosinophil patient phase amgn/azn
cover tezepelumab anti-tslp mean increas percent
predict vs baselin week
although much longer studi look detail chang volum
basi seem increas plateau somewhat four week anoth caveat
differ patient popul high low eosinophil level patient howev given
key asset investor excit asthma space highlight comparison
patient higher eosinophil higher ige tezepelumab show greater benefit
instanc week patient high liter percentag chang
baselin high dose week vs patient low
note also high patient also exhibit higher placebo respons
phase dupilumab also show higher benefit higher eosinophil patient
found notabl high eosinophil patient benefit continu grow
time low eosinophil patient benefit seem plateau
relat anab asset think suggest believ upstream
could oper similar mechan could show increas benefit
continu dose time import keep mind single-dos readout
high eosinophil patient releas
exhibit lung function dupix percentag fev
wenzel dupilumab phase present at
note anoth depict percentag increas dupix show phase
eosinophil asthma cite benefit placebo comparison
use imag show improv efficaci time seen high
eosinophil patient popul also find imag help anoth refer
phase studi high eosinophil patient howev studi show
activ low eosinophil patient could commerci differenti
phase trial enrol patient eosinophil asthma patient
high eosinophil level clinic experi dupix know
mechan activ patient popul low eosinophil level patient
risk posit data
one risk wrong patient popul select phase studi
severe-enough patient chosen
high placebo respons think largest risk previou data saw atop
dermat singl arm data given small size studi think risk
patient placebo arm could better expect respons
safeti concern think would like know given upstream
standard target perhap could immune-rel side
effect appear
commerci mani biolog develop asthma much
atop dermat
near term howev think focu phase readout proof
mechan action
longer term howev think activ compar mani
asthma biolog order assess competit
exhibit biolog develop asthma one awar
compani data cantor fitzgerald research
despit mani player asthma space still think need better biolog
xolair sale close black box warn anaphylact shock
show efficaci roughli one everi three patient
nucala cinqair must administ physician offic
fasenra approv high eosinophil patient everi eight-week subq dose
may present improv vs prior biolog
dupix pdufa date octob think advantag dupix could
efficaci indic notabl atop dermat asthma patient often
speak doctor drawback dupix asthma advers event
hypereosinophilia seen patient
question novel novel biolog asthma space
work low eosinophil patient
patient fewer biolog option tend difficult treat
long-term safeti implic
drugcompanytargetstatu asthmaadministrationxolair omalizumab rocheigeapprov everi weeksblack box anaphylaxisnucala everi week must reconstitut administ healthcar professionalcinqair everi week infus minutesblack box anaphylaxisfasenra everi week dupix pdufa octob everi weekstezepelumabamgn/azntslpphas ongoingsubq everi receptor phase ongoingmonthli cytokin phase ongoingmonthli receptor phase ongoingeveri week receptor phase ongoingmonthli ivsourc compani data august
asthma physician much-mor familiar mechan action vs newer
earli treatment biolog halt progress mild moder asthma
becom sever
evid suggest earli inhibit atop march prevent diseas
becom sever
think dupix profil asthma look highli compel vs recent approv
specif patient eosinophil greater cell per dupix led reduct
sever asthma exacerb slightli higher seen novel
biolog agent fasenra show reduct rang depend trial cinqair
iv show reduct exacerb patient higher eosinophil
nucala show exacerb reduct howev offer standard caveat
cross-trial comparison hard make
addit think efficaci patient eosinophil level could help give
dupix usag area biolog use
although exacerb reduct patient eosinophil level
compel seen higher eosinophil patient high unmet need popul
think repres addit option patient whose asthma remain uncontrol
exhibit data comparison newli approv biolog
nejm fda
think side effect hypereosinophilia may prompt question physician
import point differenti etokimab vs dupix asthma dupix rais
eosinophil level wherea etokimab appear lower eosinophil level hit well
dupix also inhibit
dupixentcinqairnucalafasenraresult elev eosinophil patient eosinophil level screen point last ratio exacerb activ vs placebo lower asthma exacerb vs everi weekiv monthlysubq monthli administ health care settingsubq everi weekseosinophil level ratio exacerb activ vs placebo lower asthma exacerb vs labelfda labelfda labelcomparison asthma phase data new biolog august
top line would expect anoth catalyst present data
think clinic measur focu import biomark eosinophil level safeti
implic durabl respons dupix increas eosinophil level led
advers event hypereosinophilia base doctor check concern
physician look impact eosinophil well
measur feno fraction exhal nitric oxid score
atop dermat phase data key de-
risk point program
view current phase data competit atop dermat
program data need hold larger patient number
review data due durabl depth respons seen phase
data highli refractori ad popul feel comfort etokimab profil
like hold larger studi
far seen singl dose uncontrol data atop dermat
patient first top-lin novemb drive stock
compani enrol placebo control phase trial atla patient
guid top-lin data
singl dose etokimab led clinic improv similar seen
multipl dose agent atop dermat
twenty-nin day receiv one dose etokimab averag easi eczema area
sever score index reduct vs baselin across patient dose fact
one dose etokimab abl show compar efficaci seen multipl
dose competitor asset demonstr strong proof activ view bode well
data given expect respons rate increas multipl dose
key risk data small sampl size earli make strong
conclus product profil
exhibit efficaci comparison easi score atop dermat data
expect etokimab efficaci increas multipl dose
clinic experi dupix biolog show longer durat dose lead
deepen respons specif dupix inhibitor saw atop dermat
qd baricitinib singledos dupix qd chang easi score day dose vs multipl dose data agentsimprov placeboplacebo respons august
respons deepen time continu suppress contrast efficaci oral
jak inhibitor appear plateau week
dupix phase show deepen respons multipl dose similar trend expect
see multipl dose anab etokimab consid asset suppress similar
phase solo trial instanc wherea averag easi reduct
four week dose averag easi reduct increas week
etokimab upstream dupix expect similar phenomenon
exhibit efficaci dupix studi
respons etokimab highli durabl suggest potenti less-frequ dose
greater efficaci multipl dose asset abl potent suppress
despit singl administr etokimab respons day still seen
patient achiev day notabl found interest proport
patient achiev actual deepen day day
view data support monthli dose vs dupix dose everi two week
think data also demonstr potenc etokimab strong durabl day
fact efficaci still seen day also support fact multipl
dose respons etokimab like deepen respons curv
exhibit anaptysbio data atop dermat studi one dose
pushback data rescu steroid allow phase protocol
could driven respons seen patient
detail know usag steroid studi
washout period prior enrol patient allow system
rescu therapi topic steroid allow studi period ethic reason
requir pi irb
howev know mani patient receiv rescu topic steroid much
may receiv may receiv
manag character use rescu steroid studi
steroid allow patient respond patient could get
topic steroid hit thu think steroid probabl affect
respons rate non-respond elig
addit patient prior enrol inadequ control topic
steroid suggest diseas could non-respons topic steroid
seven patient system non-biolog therapi washout period
control diseas vs topic steroid allow rescu
phase atla trial studi four etokimab regimen vs placebo
specif trial enrol patient plan one placebo group four cohort
differ dose regimen
term data think investor focus comparison etokimab data
profil agent space
view think etokimab data far look competit potenti could prove
superior asset atop dermat space think possibl
target greater efficaci curb inflammatori respons simpli target
addit dose regimen monthli vs everi two week could appeal physician
howev note oral develop well upadacitinib baricitinib
import keep eye
longer term think atop dermat market grow larg space room
mani player overal think atop dermat similar psoriasi rheumatoid arthriti
space room mani product chronic condit larg preval
treat moderate-to-sever atop dermat patient us think largest commerci
barrier get physician specif dermatologist comfort use biolog
think multipl pharmaceut player space encourag uptak build
awar help grow market size overal long term
commerci risk
larg establish commerci player competit
potenti oral approv
exhibit data comparison atop dermat data
drugdosingnstudy/sourcechang easi score easi score weekseasi weekseasi weekli weekli topic weekli subq standard regimen topic iv mg/kg iv day percentag body-surfac area beck et al nejm eaaci present may aad morphosi press releas feb phase data present phase phase atop dermat dataphas august
patient data two indic make
next key valu driver share
think help diversifi beyond help
valid compani platform technolog
receptor inhibitor implic sever sever form
initi studi two indic gener pustular psoriasi gpp
palmoplantar pustulosi ppp
gpp rare sever potenti life-threaten dermatolog condit wherea ppp
difficult-to-treat varieti psoriasi occur primarili hand feet
exhibit breakdown psoriasi type
preval ppp much larger gpp also much-less sever
diseas howev check think ppp poorli control exist
biolog underdiagnos could potenti larg market opportun
think ultim ppp much-larg market opportun gpp howev
two diseas similar underli biolog show posit data
gpp think investor make read potenti success ppp
howev given vastli differ preval two diseas success
gpp think compani could charg rare-diseas type price enabl anb-
still market opportun way reach market
dermatolog condit contrast success ppp gpp
psoriasisplaqu psoriasi case guttat psoriasi case pustular case gener pustular psoriasi gpp palmoplantar pustulosi ppp local case invers case
exhibit compar gpp ppp diseas
data gpp open label trial first patient data see
success think investor begin give credit gpp ppp condit
latter like much-larg market opportun compani plan start
patient trial ppp data guid
note boehring ingelheim cover also inhibitor
develop ppp gpp bi unabl find much
asset except bi studi ppp gpp phase uc asset
patient phase studi asset ppp complet enrol march
primari endpoint pppasi palmoplantar pustular psoriasi area sever index
week treatment accord clinicaltri gov studi complet juli
although know result made public
interest takeaway expert check
surpris physician thought much-great unmet need ppp
gpp sever consult spoke note ppp highli recalcitr
diseas respond well tradit biolog also report lot
ppp patient suspect underdiagnos code gener
psoriasi patient receiv reimburs biolog especi
case although patient ppp also underli plaqu
psoriasi debat literatur among physician whether ppp
form psoriasi whether diseas right physician spoke
gener pustular psoriasispalmoplantar pustulosissymptoms-larg area skin red inflammed-pus-fil blister across body-fever-fatigue-muscl weakness-organ inflamm cholangitis-pus-fil blister similar gpp hand feet-blist often harden turn dark scale patch hand feet-itch burn hand feetdiagnosisbas physic exam physic examfung cultur rule fungal infect vs pppagestyp adultstyp adultsrisk factorsmed steroidsinfectionspregnancymost patient smokersmed tnf inhibitorsinfectionscomplicationssystem infectionssepsiscan fatal controlledqu life impactstreatmentpotenti hospit support caresystem immune-suppressantstop immune-suppressantssystem immune-suppressantsu
actual report treat select case ppp psoriasi present
sever physician spoke also thought mechan could
implic psoriasi broadli gpp ppp indic could
present speedier pathway market note success gpp
ppp would want see explor potenti usag type refractori
exhibit overview gpp/ppp diseas involv
could speedi path market
interestingli think gpp could first wholli own
product could reach market even etokimab
potenti speedi pathway gpp
gpp rare form psoriasi fatal
gpp rare form pustular psoriasi character red sensit skin pus-fil
blister pustul most-sever form intern organ becom inflam lead
diseas becom fatal control repeat flare-up tend entail fever system rash
think inhibitor high likelihood success gpp
genet valid target gpp
directli target overproduc characterist gpp think
mechanist target high probabl clinic success gpp specif gpp
establish link overexpress cytokin although mani case gpp
direct genet caus mani case document stem sole mutat
caus overexpress demonstr clear link overexpress
develop gpp
approv therapeut gpp
current gpp manag cyclosporin steroid immune-suppress
methotrex notabl anti-tnf therapi known induc case gpp treatment
use first-lin agent gpp inhibitor howev shown efficaci
spoken doctor use label
think gpp alon could market opportun also approv
base nation claim data anapti found gpp patient us would expect orphan-
like price given sever gpp diseas cours also work ppp
preval us would expect much-larg product
smaller proport sale come gpp would expect product price much
work gpp increas confid work ppp
larger opportun two ppp palmoplantar pustulosi thu think proof
concept gpp import get investor pay attent potenti opportun
reason think work gpp
genet valid target mutat caus gpp
upregul gpp patient gpp pustul
clinic data show efficaci anakinra inhibitor downstream
overview gpp patholog genet link gpp mutat key
reason could work gpp
gpp genet origin defici receptor antagonist
mani patient gpp mutat gene receptor antagonist ra
anti-inflammatori cytokin modul level mutat gene encod
found result gpp wide express skin
typic mediat level patient gpp lower level
antagonist lead enhanc inflammatori respons
patient ditra defici interleukin thirty-six receptor antagonist lack antagonist
lead higher level signal lead increas level cytokin
 downstream inflammatori cascad
gpp occur patient without prior tradit psoriasi
gpp occur patient prior present psoriasi vulgari plaqu psoriasi
patient diseas first present gpp
commonli case gpp without tradit psoriasi genet variant
case patient gpp without tradit psoriasi usual occur patient homozyg
heterozyg mutat gene report sugiura patient
develop gpp prior histori typic psoriasi usual mutat
debat scientif commun whether group patient
classifi differ subtyp gpp whether similar underli patholog
specif discuss whether patient mutat patient
prior psoriasi differ subtyp underli caus gpp diseas thu respond
differ treatment know answer think import look
evalu subgroup data dose gpp patient
regardless import view presenc mutat caus
diseas demonstr strong link gpp patholog patient without
underli skin inflammatori process suscept develop diseas
upregul patient without mutat still demonstr elev
current treatment gpp base manag acut flare-up
think need better mainten therapi prevent
speak physician learn exist immune-suppress reason efficaci
manag acut sever flare-up physician spoke report use strong immune-
suppress agent initi discontinu treatment flare-up resolv due
safeti concern agent patient respond physician tri varieti
differ immune-suppress agent physician spoke note abl control
flare-up patient gpp
howev think strong need agent also use mainten
set patient whose flare-up easili control
physician report switch anti-tnf use high intens immune-suppress
flare-up order prevent flare-up gpp indic anti-
tnf effect mainten agent
goal treatment gpp get immun reaction flare-up control
end varieti immune-suppress use vari efficaci
lot data efficaci agent use typic gpp acitretin
methotrex cyclosporin check physician medic effect
initi get diseas control patient may experi addit flare-up
especi case mani therapi acitretin recommend long-term
usag due safeti concern
physician spoke use label inhibitor inhibitor
limit data efficaci agent agent formal approv
condit
exhibit treatment paradigm gpp
drawback current avail agent support need better treatment gpp
especi treatment safe chronic use vs simpli use acut set
acitretin effect use commonli signific safeti concern limit
chronic usag guidelin recommend first agent use treat gpp studi
shown effect control gpp flare-up howev use drug
limit refractori type sever psoriasi caus sever birth defect
liver damag thu chronic usag ideal patient typic treat
acitretin flare-up wean flare control leav
patient risk futur flare-up
cyclosporin effect safeti concern limit chronic usag cyclosporin tie
increas risk skin malign caus system hypertens
methotrex effect safeti concern specif birth defect liver
toxicity/fibrosis/cirrhosi prolong use acut alt/ast abnorm increas
risk malign document methotrex onset activ
also slower vs cyslosporin acitretin
tnf inhibitor high rate infect seen gpp patient treat
anti-tnf gpp patient alreadi high risk infect physician seem
prefer use remicad humira enbrel tnf treat
gpp studi avail data shown remicad shorter time
remiss vs humira enbrel gpp patient tnf show efficaci control
gpp flare mani patient doctor spoke mention tnf work
effect control gpp patient howev view drug
better efficacy/safeti combin would meaning uptak infect
risk associ tnf specif gpp patient high risk infect
begin
medic board nation psoriasi foundat guidelin kalb lineacitreinclyclosporinmethotrexateinfliximab remicad second cosentyx taltz tnf humira enbrel puva combin topic
exhibit summar effiaci safeti tnf inhibitor gpp
think like preval gpp underestim industri literatur
could find mani paper on-line discuss preval gpp howev found
preval vari wide treatment paradigm rel similar
difficult-to-treat skin condit extens usag immune-suppress diseas
control like littl need differenti diagnosi gpp
exhibit preval gpp literatur
everi physician spoke seen case gpp case compar typic
plaqu psoriasi even ppp patient expect
preval estimateimpli us per per per per look us nation claim datasourc compani data sourc cite abovepreval estim gpp august
speak doctor got sens gpp rare doctor spoke
seen hand case case diseas present clinic practic everi month
major academ center hand patient care condit
sever on-going recent complet studi biolog gpp japan
limit detail studi potenti data
unsur statu phase trial albeit small ran adalimumab
risankizumab gpp patient japan cover also current run trial
guselkumab japan gpp patient
exhibit studi way gpp could find
compani data clinicaltri gov
phase studi open label studi monthli dose
primari endpoint efficaci base cgi clinician global impress scale
cgi assess physician patient classifi five categori much
improv much improv minim improv chang worsen
patient consid clinic respons physician grade much
improv much improv minim improv primari endpoint studi
determin proport patient clinic respons base grade scale
exhibit studi design gpp
targetdrugcompanyphasestudi namenprimari complet multicent open-label studi adalimumab japanes subject gener pustular actual date per phase random open-label studi assess efficaci safeti differ dose regimen risankizumab administ subcutan japanes subject gener pustular psoriasi erythroderm actual date per phase multicent open-label studi evalu efficaci safeti guselkumab treatment subject gener pustular psoriasi erythroderm per singl arm multipl dose studi assess efficaci safeti subject gener pustular data guid clinicaltri gov compani data
stock perspect think investor mostli care proof activ vs
superior therapi gpp sinc limit avail comparison
manag note on-going gpp studi involv highli sever patient thu think
even small proport transit chronic usag toxic immune-suppress
exampl retinoid cyclosporin would meaning data
think success gpp demonstr divers pipelin anoth clinic
also think activ gpp import read-through potenti efficaci
much-larg indic ppp
limit detail clinic studi done gpp make difficult make
comparison small studi primarili done japan
studi found gpp speak manag
think good comparison patient much-mild condit
enrol studi specif enrol patient baselin
jda score higher denot highli sever patient think comparison
valu howev think investor want see comparison refer
exhibit gpp studi inhibitor
subqno placeboopen weeksprimari endpointproport subject achiev clinic respons clinic global impress cgi scaleincid advers event week endpointsjapanes dermatolog associ sever mjda dermatolog life qualiti instrument dlqi gpp studi remiss improv patientsyamasaki achiev spga week success measur cgi achiev patient week global impress improv static physician global assessmentgpp studi could find august
compani data clinicaltri gov
gpp
think ppp could market opportun phase data guid
could key valu driver share
think littl credit given ppp think
success could signific market opportun ppp
doctor spoke report ppp highli preval condit practic
larg proport ppp patient difficult treat fail mani
ppp pus-fil blister hand feet often harden scale
pustul pu fill blister seen gpp also seen ppp pustul typic form
hand feet itchi pain inhibit day-to-day activ although
condit life-threaten pustul often dri thicken becom harden scale around
skin result confus fungal infect similar gpp anti-tnf treatment
actual trigger flare-up vs help control flare-up
larg preval ppp highli preval form psoriasi estim
patient us
unmet need limit activ exist biolog speak sever
dermatologist learn ppp remain key unmet need practic
diseas often respond tradit immune-suppress off-label biolog
 anti-tnf think good thing bad thing
one hand unmet need high highli preval popul
hand could recalcitr patient popul complic biolog
highli disrupt diseas qualiti life blister occur hand feet
diseas highli disrupt patient qualiti life pain walk pain use
hand although diseas sever gpp life-threaten
check suggest ppp patient persist seek addit therapi
disrupt blister hand feet
initi patient data anapti plan initi multi-dos placebo
control trial ppp top-lin data guid
reason could work ppp
express higher level ppp pustul biopsi vs suggest
recent literatur shown upregul plaqu psoriasi pustular psoriasi
gener broader psoriat disord ppp
preclin model ppp psoriasi gener show efficaci
mutat found gpp patient also seen ppp patient albeit
also link broader plaqu psoriasi indic also point mani
physician spoke mention
psoriat lesion found higher level gene express
express found highli correl level
tnf-alpha target know implic ppp psoriasi gener
receptor commonli found skin
major plaqu psoriasi patient elev ratio agonist/receptor
wherea minor ra crohn patient elev suggest uniqu
inflammatori involv skin condit although note bi studi
uc
exhibit ppp studi could inconclus result exist biolog
compani data clinicaltri gov
patient othersbissonnett statist signific differ vs placebobissonnett signific improvemetn vs placeboterui ppp studi could find
present ppp market estim think market potenti could peak
addit valuat scenario base model work
etokimab bull scenario increas probabl etokimab
dcf increas
increas probabl success etokimab asthma atop dermat
indic vs respect base case dcf increas
upsid base case model probabl etokimab asthma
ad dcf increas higher current market price
longer term etokimab success indic model
asthma atop dermat dcf increas increas vs
exhibit etokimab bull scenario greater confid
etokimab super bear downsid risk base case etokimab
unsuccess
success etokimab full valu fv would depend
much credit give etokimab complet fail see data anb-
although think outright failur highli unlik would expect share trade
closer cash tsro collabor revenu would
downsid vs base case
also consid scenario success clinic develop
leav etokimab estim unchang
bull scenario credit gpp ppp could worth
overal valuat would etokimab assumpt unchang
credit gpp ppp would worth overal dcf would
investor get increment comfort etokimab ad asthma
base case see impress sign activ gpp ppp think could provid
share meaning upsid current level probabl ppp
gpp specif base dcf credit gpp ppp could worth
could worth
think offer import piec diversif case etokimab data disappoint
investor becom bearish market opportun competit landscap
exhibit bull scenario
credit
think program
could worth
success
bull scenario etokimab readout success
think share could end year high base dcf
fundament basi dcf assign credit etokimab credit anb-
gpp ppp dcf would worth solid data etokimab
asthma readout well phase atla atop dermat trial
think investor becom comfort asset modal assign credit
similarli strong data gpp ppp studi think investor begin pay
attent give credit asset well super bull scenario success etokimab
gpp ppp dcf valuat share would
exhibit bull scenario
clinic readout success think becom topic convers
small compani limit commerci infrastructur current although think
could build commerci capabl think either clinic asset show
strong efficaci investor could begin view compani valuat perspect
much valu could add strateg parti vs stand-alone compani
exhibit scenario analysi base model
clinic asset de-risk see meaning upsid peak sale multipl
assign potenti product sale also think clinic asset de-risk
import stock driver level
probabl success unadjust sale adjust atop market peanut sale sale multipl cantor equiti research year launch august
worst case scenario etokimab fail think share could trade low
cash npv tsro mileston although base case assumpt
suggest dcf would
rule outsiz loss share point either especi
recogn still lot downsid potenti etokimab especi upcom asthma
data although think complet failur etokimab unlik base
current know asset
comfort downsid risk etokimab ahead come asthma readout
see downsid protect readout beyond
key reason uncomfort potenti downsid diversif forese
potenti success
etokimab fail show promis success think share
could trade time
success etokimab program dcf would without
lower expens success alon dcf share would
said think investor may need see sever stage readout
becom comfort asset
exhibit scenario analysi suc
exampl etokimab total failur see strong proof-of-concept data
gpp ppp think share could recov time valu
valuat risk
price target overweight rate base probabl adjust dcf extend
estim assum discount rate line anab small-cap peer assign
share termin valu growth rate line peer
deriv revenu estim assign probabl success etokimab atop
dermat probabl success etokimab asthma probabl success
etokimab crswnp peak probabl adjust sale indic result
ad asthma crswnp respect assign
probabl success gpp ppp respect probabl adjust sale estim
includ model gpp ppp
base net work growth termin market sale per sensit assum sale market august
clinic trial enrol speed may slower compani forecast result
delay clinic trial readout timelin would put revenu estim risk
either program due delay develop
lack efficaci etokimab atop dermat asthma crswnp would put
revenu estim risk either program due delay develop
safeti issu aris etokimab would put revenu estim risk
either program due delay develop
lack efficaci safeti concern either gpp ppp would
put revenu estim risk either program due delay develop
better-than-expect data commerci competitor asthma atop dermat gpp
ppp crswnp could result much-smal market opportun forecast
includ key manag biographi websit refer
hamza suria appoint ceo sinc led transform
earli platform technolog focu develop robust antibodi product pipelin across key
therapeut area prior mr suria maxygen respons
partner allianc manag next-gener protein therapeut oncolog support
care hematolog autoimmun includ partnership roch sanofi-aventi bayer
astella mr suria hold sc biochemistri kalamazoo colleg immunolog
univers western ontario execut richard ivey school
busi mr suria graduat mercersburg academi
marco londei join bristol-my squibb bm
therapeut area head immunosci respons earli clinic translat research
portfolio immune-rel therapeut prior bm dr londei global head
autoimmun translat medicin novarti translat scienc offic genom
institut novarti research foundat led design execut earli
stage clinic studi novarti bm includ develop secukinumab canakinumab
sever biolog therapi immune-medi inflammatori diseas dr londei receiv
faculti medicin univers bologna conduct post-doctor
studi tumor immunolog london uk key member team pioneer
develop anti-tnf therapi kennedi institut rheumatolog kir faculti
medicin imperi colleg london dr londei professor faculti medicin imperi
colleg london professor autoimmun gastroenterolog consult univers
colleg london prior join novarti wide recogn world-class contributor
inflamm publish peer-review paper field autoimmun self-
recognit immun modulatori checkpoint
domin piscitelli join chief offic januari
year industri experi experi commerci product launch xtandi
tarceva market partnership in-licens transact acquisit debt equiti
financ prior join mr piscitelli vice presid financ strategi
investor relat mediv inc play key role acquisit
mr piscitelli serv senior director collabor oper financ
astella pharmaceut mr piscitelli serv variou role increas
respons culmin vice presid treasuri manag financ osi
pharmaceut play signific role acquisit astella pharmaceut mr
piscitelli hold bachelor degre account master degre financ certifi
cantor fitzgerald statement million except per share adj product product product product oper expens profit/ loss non-gaap expens net paid benefit tax income/ loss weight average share weight average share basic dilut basic dilut
valuat assumptionsprob success unadjust sale adjust salesdcf atop market peanut sale sale multipl cantor equiti research year launch revenu salesatop adjust salesatop probabl adjust probabl unadjust sale adjust sale
cantor fitzgerald sale sale adultsatop dermat preval moder treat moder steroid topic jak uncontrol mod-sever mod-sever total diagnos biologics/jak price effect atop derm sale us
anaptysbiocantor fitzgerald build diagnos moder biolog penetration- price discount effect
compani report cantor fitzgerald research
cantor fitzgerald balanc sheet million except per share asset cash tax incent expens current current equip long term equitycurr liabil account payabl current current current payabl net current paid comprehens stockhold equiti liabil convert prefer stock stockhold equiti
compani report cantor fitzgerald research
cantor fitzgerald statement million except per share flow oper activ net reconcil net loss net cash use oper activ depreci fair valu liabil prefer stock interest dispos properti oper asset liabil receiv collabor tax incent expens payabl tax cash use oper flow invest activ acquisit matur properti cash use invest flow financ activ proce public offer net underwrit issuanc common stock upon exercis stock issuanc prefer stock net issuanc cash provid financ increas decreas cash cash equival restrict cash equival restrict cash begin cash equival restrict cash end august
platform technolog multipl clinic stage
asset key catalyst horizon
call mani reason believ see mani clinic
success platform think current level leav room
meaning upsid clinic asset valid
compani overview clinic stage platform compani multipl clinic stage
asset lead asset etokimab studi mani allerg condit among
anab asset etokimab furthest ahead atop dermat early-stag data
octob sent share think meaning de-risk left
etokimab see multipl clinic catalyst next month key valu driver addit
clinic asset notabl add key piec diversif initi readout expect
believ underappreci
clinic stage platform technolog compani multipl clinic stage
asset compani platform technolog util human bodi endogen antibodi
creation mechan creat larger number potent antibodi therapeut target
earli valid platform seen etokimab atop dermat well
sever immuno-oncolog asset anapti licens tesaro tsro
cover includ clinic studi
compani lead asset etokimab studi mani allerg
indic etokimab target implic across mani allerg condit
asset studi atop dermat skin diseas similar eczema asthma
chronic sinus nasal polyp think strong scientif clinic valid
suggest could strong activ indic
among anab asset etokimab furthest ahead atop dermat
seen earli proof activ phase compani move etokimab
success think etokimab could achiev sale ad asthma think lead asset etokimab succes allerg diseasesif success think could sell gpp ppp think underappreci key upsid driverbi ye patient data etokimab patient vs current multipl etokimab readout next month give potenti meaning de-riskinginiti gpp data give us sens efficaci pathway think ppp remain unmet attract market opportunityw think opportun come focu broader macro trend see play timesupport view potenti target think atop dermat asthma underappreci market etokimab asthma data etokimab ad gpp data ppp datakey catalyst
phase trial diseas etokimab demonstr activ phase trial
atop dermat form eczema patient patient receiv one dose
etokimab show meaning clinic improv vs baselin core investor
pushback singl arm placebo studi also allow rescu topic
steroid perhap make earli draw conclus compani move etokimab
larger phase trial help answer question drug
addit pipelin asset continu move forward think add import
point diversif stori next month specif move
inhibitor clinic two rare skin diseas patient data
expect think asset underappreci think could repres
anoth meaning commerci opportun
exhibit overview portfolio
think target diseas area could grow major therapeut
categori time
atop dermat allerg asthma chronic sinus nasal polyp therapeut
option patient mani diseas immunolog psoriasi rheumatoid arthriti ra
fairli crowd therapeut option note anti-tumor necrosi factor tnf
deriv larg portion sale ra psoriasi sale approxim
addit indic like atop dermat allerg asthma similar preval rate
diseas sever far-few biolog approv comparison creat
attract opportun address unmet need accord check immunolog
key view payer creat competit due amount therapeut categori like
ra psoriasi
key part thesi given think etokimab could sale
categori success studi high-growth indic unmet need
anab etokimab
rel categori
rheumatoid arthriti
diseas area
 us indic popul vs number approv origin biolog target us patient popul sizeapprov origin biolog
think clinic catalyst single-most import stock driver
share next month
think single-most import stock driver clinic readout portfolio
exhibit catalyst view stock impact
compani data cantor fitzgerald research
even though think consider think key stock focu
clinic success platform even see posit readout competitor
abbvi cover upadacitinib regeneron cover
think import focu stock level market cap vs potenti peak
sale etokimab whether asset work technolog platform becom
exhibit cantor view stock driver month
compani data cantor fitzgerald research
clinic data updatesetokimab atop dermat dataetokimab asthma ppp gpp dataetokimab crswnp datacompetitor dataoth inhibitor data updat ad phase data updacitinib phase data crswnp new indic discuss target checkpoint agonist conditionsi commerci dynamicsdupix launch atop dermat asthma upadacitinib ra file safeti develop high dose get approv drugindicationcatalystwhenstock top-line rhinosinus w/nasal polypsiniti phase eclips trialyear end pustulosi ppp initi phase pustular psoriasi gpp gallop phase top-line dataearli dermatitisatla phase top-line pustulosi ppp phase top-line rhinosinus w/nasal polypseclips phase upcom catalyst august
think underappreci asset could
major driver share
report conduct detail analysi think next
product receiv investor focu stori
report discuss opportun could indic gpp ppp
think import data expect import consid
stock behav readout asthma asthma readout regardless outcom
think investor pivot evalu
inhibitor clinic develop rare dermatolog skin condit
think asset underappreci investor could import upsid driver
clinic data releas
exhibit background indic gpp ppp
compani data cantor fitzgerald research
ppp could blockbust opportun data expect review
literatur think ppp palmoplatar pustulosi could meaning market
opportun larg number patient exist biolog
littl impact diseas actual remind us atop dermat
gpp data expect could first commerci indic
launch think genet valid efficaci gpp
gener pustular psoriasi strong gpp sever diseas see
path market success although think market opportun gpp rel
small think success could turn investor attent ppp gpp serv initi
proof concept
see ppp larger opportun think gpp gateway investor
begin assign credit ppp view larger long-term market opportun
two diseas similar underli patholog think initi data gpp
help investor becom comfort ppp market opportun
gpppppdiseasegener pustular psoriasispalmoplantar pustulosisu bodi multi-organ inflammatori condit fatalharden pustul hand feet signific impact qualiti lifecurr treatmentscantor forecast label cyclosporin retinoid biolog noth approv specif either diseas rare diseas price approv ppp assum price would much lower ppp would main sourc revenu august
probabl success gpp ppp would worth
base dcf
think investor current assign littl credit program thu see favor
risk-reward ahead initi clinic data readout gpp ppp indic
term core valuat compani lot
confid lead asset etokimab continu drive valu
mani etokimab readout horizon could serv major inflect point stori
current data etokimab earli small number key point
investor pushback stori howev think get data etokimab
could major inflect point stori
next month expect multipl readout etokimab allerg diseas much
larger patient number think readout serv key de-risk point asset
key driver either posit neg stock perform
exhibit view etokimab viabl target
compani data cantor fitzgerald research
upcom asthma data key near-term stock focu
good data look benefit placebo mid-to-high singl
think investor look liter improv versu baselin
think most-relev clinic comparison phase dupix data wenzel
show dupix benefit placebo high eosinophil patient
reason think work asthma
proof concept dupix inhibitor asthma
inhibit individu shown efficaci target
improv eosinophil asthma
extens literatur demonstr key role asthma
hit clinic proven target etokimab inhibit think also inhibit clinic proven allerg target multipl commerci drug activ earli data earli phase data atop dermat even peanut allergi demonstr activ allerg scienfic research target extens scientif literatur document role play allerg pharma player seem agre target alon identifi promis target think good thing share ahead data summari reason think etokimab readout could success august
mani clinic preclin model shown key sustain asthmat
respons allergen instanc loss function mutat shown
offer protect asthma
activ atop dermat diseas similar underli
mechan eosinophil asthma
clinic activ atop dermat anoth allerg eosinophil condit
show activ eosinophil allerg diseas mani patient
atop dermat also asthma vice versa underli immun irregular
often
activ reduc asthmat exacerb phase peanut allergi
although data peanut allergi overli compel oral food
challeng opinion benefit seen asthma symptom patient
treat specif dose patient concomit allergi
symptom rhiniti pruritu uticaria asthma flare nut allergi vs
larg pharma move inhibitor forward asthma stealth mode
could suggest earli clinic activ seen intern earli stage
studi compani instanc roch cover move patient
phase asthma move patient asthma studi
success think etokimab could sale
could sale
base case probabl adjust base clinic progress sale
estim
unadjust sale estim success indic close
base case adjust revenu indic includ estim
exhibit unadjust sale successfulsourc cantor fitzgerald base case sale estim base case sale estim etokimabsourc cantor fitzgerald researchsourc cantor fitzgerald august
valuat see upsid clinic readout next
assign credit etokimab atop dermat asthma
ppp gpp respect
think two most-import stock driver anab share next month
understand etokimab clinic profil
earli data clinic stage asset
exhibit overview cantor base valuat
exhibit overview cantor base valuat assumpt
probabl success unadjust sale adjust atop market peanut sale sale multipl cantor equiti research year launch august
pictur see positive/risk reward mani clinic catalyst
current cash tesaro royalti worth valuat
exhibit variou risk/reward scenario base model analysi
includ rang scenario includ valuat model analysi
exhibit variou risk/reward scenario base model analysi
includ scenario analysi clinic probabl success asthma
atop dermat fair valuat output model
pricebear basebul avaluationcantor take potenti stock scenariosscenariovalu upside/downsidewhat happensbear complet failuresbear etokimab efficaci limit efficaci data credit etokimab limit credit etokimab discontinu investor give credit base probabl adjust credit etokimab increas success etokimab chang assumptionsbul increas success etokimab ppp gppbull use peak sale multipl peak probabl adj sale
upside/downsideneg asthma stock herecantor ad/asthma assumptionsposit asthma dermat po asthma po
risk pushback overview stock debat
lot controversi surround name etokimab work think
lead meaning upsid current level
summar key stock debat stand key topic focu whether clinic
program asthma atop dermat work valid data seen far
discuss point includ debat whether larg market whether anab
etokimab even success get overshadow drug larger commerci player
stock debatebackgroundbear say bull say cantor thoughtsasthma data work activ placebo singl dose etokimabw think investor look benefit placebolimit clinic data etokimab make hard inhibit mani target alon know work asthma could even activ would surpris etokimab show least activ asthma think like activ target asthma etokimab success inhibit think key risk small size trial atop dermat data hold larger trial phase trial patient enrol data guid data small sampl size placebo controlrescu topic steroid inhibit target know work data singl dose competit multipl dose data highli durablew think multipl dose increas efficaci product vs seen singl dose even placebo respons impact steroid think effect multipl dose lead competit efficaci market size larg ad asthma market dermatologist like use biologics/ad sever diseas asthma crowd marketsimilar preval indic ra psoriasi larg biolog market think ad asthma grow becom larg brand market chronic indic sever impact qualiti life similar preval larg space competit ad/asthma market crowd ad asthma crowd market compet much larger compani oral inhibitor developmentrel number product ra psoriasi competit smallsafeti jak inhibitor concernoth target receptor cytokinew think mani player help grow overal market size also cautiou jak inhibitor safeti infect vte ad stock perspect think import focu proof efficaci etokimab valid platform sourc compani data cantor research august
stock debat near-term data readout asthma think
could lead upsid depend data qualiti
downsid think share could trade low weak data thu
flag risk/reward balanc slightli neg event program complet
failur doomsday scenario safeti event think share could trade low
think unlik scenario
major anab market cap current attribut etokimab
asthma trial show bad outcom sign activ think could
signific downsid risk hand etokimab shown work asthma think
investor posit view atop dermat data
basic asthma data asthma key read entir platform
would thu expect share highli volatil around event
read atop dermat given limit data atop dermat program to-
date posit neg read asthma program could make investor feel either
lot lot less comfort atop dermat program note
asthma studi placebo control wherea atop dermat data read
to-dat
similar diseas key market opportun two diseas similar underli
allerg caus overlap patient popul thu think investor would look
likelihood success phase atop dermat data size
etokimab market opportun asthma data neg
exhibit scenario analysi upcom asthma data
think
downsid
base
think
could see
data
compani cash per share estim tesaro tsro cover
royalti npv basi worth thu estim worst-cas scenario
stock would worth
outputetokimab inputprob adj etokimab salesdcf upside/downsidesup bull casehighli posit data much better benefit vs success asthma atop caseposit asthma data compar benefit vs success etokimab po bear caseweak efficaci show benefit vs po etokimab bear casei discontinu entir etokimab programno effect safeti tsro cantor equiti researchcurr market pricescenario august
stock debat atop dermat data hold
despit limit data think earli data show strong signal singl
dose expect efficaci increas multipl dose
overal think phase data although small number show depth durabl
respons would highli unlik ineffect molecul also think
multipl dose etokimab longer studi deepen effect instanc saw
dupix depth respons deepen sustain dose inhibit
similar mechan think could similar effect etokimab
exhibit thought atop dermat data
bear case data bull responsecantor atop dermat phase patient trial placebo control small patient set might high placebo response-th respons rate much higher seen placebo arm atop dermat trial seen data -patient receiv dose placebo day saw minim respons dose day sever patient popul vs ad trial placebo effect could lower vs ad studi -durabl respons day would also inconsist placebo responsew think could placebo effect seen patient overal phase ad data despit small number show efficaci highli refractori patient popul would unlik seen inact drug rescu steroid allow atop dermat phase trial could led respons seen trial-top steroid oral allow small amount exact amount protocol disclos patient allow rescu usag nonrespond could use steroid hit thu steroid could technic contribut response-manag said bump easi score seen result steroid usage- think unlik steroid impact result think indic activ rule possibl steroid usag led improv averag easi reduct rate although inclin think impact small trial could enrol right patient -becaus patient popul sever lower probabl trial enrol right patient super respond think risk data hold larger patient number think like scenario simpli respons rate would high confid activ drug upstream work complimentari way cytokin believ studi dupix combin mani scientif public document fact inhibit also lower level think could signal mechan activ outsid key risk etokimab long term howev look literatur speak basic scienc immunologist think inhibit could enough lead clinic meaning result epeci light literatur show predomin pathway lead sustain vs transient immun reaction august
stock debat longer term think market opportun
target key area growth therapeut space
think allerg diseas one anapti studi could next commerci
frontier space
 inflamm immunolog space biotech largest-sel drug includ
abbv humira amgn enbrel wherea chronic inflammatori diseas
arthriti dozen approv biolog includ drug humira
enbrel chronic inflammatori diseas atop dermat allerg asthma chronic
sinus far-few approv biolog think diseas repres major growth
opportun novel therapeut consid prior biolog shown limit efficaci
treat diseas
exhibit immunolog popul vs number approv drug
studi atop
derm asthma
rel categori
arthriti diseas
area
compani data cantor fitzgerald research
anti-tnf tumor necrosi factor inhibitor class sale global see mani
similar anti-tnf market allerg condit studi
look size anti-tnf inhibitor class earn signific portion sale
rheumatoid arthriti ra psoriasi see mani similar atop dermat
allerg asthma space chronic inflammatori condit larg preval
larg impact patient qualiti life atop dermat allerg asthma similar patient
preval ra psoriasi far-few approv biolog
biolog reach penetr atop dermat ra estim
atop dermat would market global
although assum base case think interest sensit
think growth potenti atop dermat biolog reach penetr ad similar
alreadi achiev ra sensit support view mani player ad long
term may help grow usag biolog may expand overal size market
sensit assum biolog may penetr patient popul treat moderate-to-
sever ad treat ra patient receiv biolog figur roch
cover diagnos ra treat therapi biolog
 us indic popul vs number approv origin biolog target us patient popul sizeapprov origin biolog
non-biolog contrast sensit calcul assum ad
diagnos patient us treat vs ra account fact
mild patient ad might go without treatment
exhibit anti-tnf market associ sale
us diagnos ra patient treat biolog
roch publish estim diagnos ra patient us
treat treat biolog suggest us
diagnos ra treat biolog treat ra treat
contrast base case model diagnos ad patient
treat biolog jak still much lower vs ra market
atop dermat estim patient us treat moderate-to-
sever condit model ad patient us treat biolog
jak inhibitor penetr rate total number diagnos ad patient
although think treatment paradigm allerg condit includ biolog may take
time evolv think signific area growth biolog long
current pushback physician treat atop dermat allerg asthma
comfort biolog heard doctor check well howev think
paradigm evolv chang time physician increas experi
agent compar biolog mani current treatment allerg diseas
 steroid cyclosporin think clear medic rational efficaci
safeti perspect greater biolog usag diseas
base case model assumpt atop dermat space penetr
although view ad market probabl much-mor bullish note still
model significantli fewer ad patient ra patient treat biolog
exhibit cantor biolog penetr patient number forecast atop dermat
note ra assumpt approxim assum minim penetr growth
illustr purpos compar ra vs ad
exhibit cantor take us atop dermat market size
 penetr diagnos patientsu biolog treat patientsu ad biolog treatedu ra biolog treat thousand us ra biolog penetr diagnos us ad biolog penetr market shareu annual ad market sale us atop dermat salestot ad us biolog sale player us ad sale probabl adjust us market share august
stock debat think competit updat
major driver share level
howev bear case atop dermat asthma crowd market
mani novel agent develop agent similar mechan action
also target show exhibit louis chen
cover lilli louis chen cover
overal think larg market room mani player mani competitor
program compon efficaci safeti could inhibit approvability/commerci
uptak establish clinic efficaci asset could strong strateg addit
portfolio player market
exhibit overview commerci debat
jak inhibitorsoth inhibitorssummarythes oral product develop atop dermat well ra lly/inci jak inhibitor phase atop dermat sever player regn/sni gsk inhibitor developmentpotenti headwind inhibitor breakthrough design ad-fast act short time efficacy- especi establish player space could bundl jak product deal w/payers-if equival efficacy/toler etokimab class could evolv mani asset view similarli doctor larger player could advantagepotenti tailwind safeti concern concern vte clot infect risk could limit uptak and/or prevent regulatori approv doses- commerci dermatologist could sensit infect rates-th inhibitor develop target receptor cytokin etokimab could limit efficaci and/or tolerabilitypotenti updat jak safeti upadacitinib file ra mid color file phase atop dermat data potenti asthma phase data trial complet enrol april august
think competit updat could greatest impact share
roch cover regeneron cover glaxosmithklin
gsk cover inhibitor
regn/sni asthma phase trial inhibitor compani
said littl seen clinic preclin asset
think possibl updat either program releas base
timelin outlin clinicaltri gov specif accord clinicaltri gov
inihibitor complet enrol asthma phase trial april
could put data disclosed/pres regn phase asthma trial combin
w/dupix clinicaltri gov estim primari complet date septemb
trial still enrol
stock perspect think downsid upsid ahead
competit data updat especi competitor larg compani may
disclos data posit
present key competit updat watch mani
sure compani top-lin even disclos data trial
phase trial
outsid trial think pfizer could first phase
atop dermat readout jade mono wich clinicaltri gov primari complet date
often inaccur march trial began enrol late
think could upsid share fda review upadacitib ra reveal
regulatori concern safeti asset
think abbv upadacitinib well pfe view key competitor
ad space discuss chart thu safeti concern aris regulatori perspect
 potenti adcom part label think could view favor
investor biolog ad space dupix etokimab
exhibit summari competitor program clinic potenti upcom updat
mani competitor atop dermat space hightlight program
watch close
exhibit summari atop dermat program clinic
drugcompanystag admoacommentsdupilimab design adupadacitinibabbvphas inhibitorbreakthrough design adbaricitinib olimi lly/incyphas inhibitorbreakthrough design adamg ep callcompetit landscap moder sever atop dermat ad assetcompanytargetprogramwhatestim ad program- dose first patient juli patient trialtoplin phase ad data late depend enrol randa file ra expect detail safeti commerci potenti approv process/labelingmid color safeti ad program dose first patient decemb current enrol multipl phase trial potenti top-line ad data primari complet ct gov march jade mono studyamg subq asthma phase complet enrol april primari endpoint weeks- phase asthma data- disclos asthma program combo w/dupi- current enrol first patient dose march studi everi week subq asthma vs dupix monotherapi dupix combin potenti asthma phase data- clinicaltri gov list sep estim primari complet iv asthma phase current enrol began enrol april primari endpoint mid disclos data clinicaltri gov list feb estim primari complet date
show competitor asthma well mani market alreadi unmet need remain
exhibit asthma therapi market pipelin
drugcompanytargetstatu asthmaadministrationxolair omalizumab rocheigeapprov everi weeksblack box anaphylaxisnucala everi week must reconstitut administ healthcar professionalcinqair everi week infus minutesblack box anaphylaxisfasenra everi week dupix pdufa octob everi weekstezepelumabamgn/azntslpphas ongoingsubq everi receptor phase ongoingmonthli cytokin phase ongoingmonthli receptor phase ongoingeveri week receptor phase ongoingmonthli ivsourc compani data august
inhibitor list descript full catalyst chart
includ detail around inhibitor key program develop
exhibit inhibitor develop
also includ key catalyst space focus
exhibit catalyst watch month
moleculecompanyreceptor/cytokinedevelop stagestatusestim on-going atop dermatitisphas on-going asthmaasthma phase top-line phase top-line subq asthma phase complet enrol april primari endpoint week mid phase asthma data studi copd phase week subq asthma phase vs dupix monotherapi dupix combin list sep estim primari complet datealso studi copd phase iv asthma phase began enrol april primari endpoint mid list feb estim primari complet datealso studi allerg fungal airway diseas began recruit april ep call phase start data disclosedroch asthma trial asthma trial inhibitor develop awar cantor fitzgerald research compani data mid list feb estim primari complet dateamg enrol april week recruit clinicaltri gov list sep estim primari complet dermatitisphas co guidanc august
technolog use human immun system make
antibodi gener technolog use endogen human
process creat antigen enabl compani creat antibodi diseas target
hard effect neutral antibodi gener method
despit mani commerci therapeut antibodi still limit
exist antibodi platform abl accomplish
antibodi natur occur product bodi immun system
bodi white blood cell produc varieti antibodi order protect bodi
pathogen harm bacteria antibodi bind target antigen attempt
antibodi neutral target antibodi also manufactur treat diseas
target becom major class drug
first manufactur antibodi therapeut purpos approv
sinc time field therapeut antibodi grown dramat modal
howev still limit current antibodi technolog abl
despit advanc antibodi select engin mani target remain difficult
neutral variou antibodi technolog base mous yeast model creat
antibodi certain target low potenc limit function activ bind
wrong part target difficult manufactur
see room new antibodi develop platform target
platform unabl
despit larg number approv antibodi think still room improv
antibodi platform technolog target next wave diseas previous
hard dose therapeut
technolog util human bodi intern antibodi gener
process identifi potent antibodi tradit hard-to-target antigen
contrast therapeut antibodi gener use mous model
human bodi endogen abil creat antibodi varieti harm
order adapt varieti immun challeng human bodi endogen
process call somat hypermut shm order creat antibodi need
particular immun threat enabl bodi respond pathogen ad-hoc basi
depend specif pathogen
anaptyss technolog identifi enzym induc human antibodi
format vitro cell system
specif technolog use enzym activation-induc cytidin deaminas
aid natur activ human bodi encount pathogen
need build antibodi although vivo human usag technolog
unabl creat antibodi use aid enzym initi shm somat
hypermut mammalian cell system
exhibit overview somat hypermut vitro process
antibodi gener model limit divers potenc antibodi
creat
anoth process antibodi creation inject mous antigen desir
target neutral replic result antibodi mous produc
although produc mani effect antibodi therapeut mouse-gener
antibodi alway translat effect target neutral human mous
immun system respond antigen time antibodi gener often
effect neutral given target human gener antibodi might
use human immun system abl gener antibodi
specif anab technolog abl gener wide varieti antibodi use
human shm somat hypermut process human shm antibodi product
process typic produc mani antibodi vs model mous give
larg select antibodi given target choos tri find
potent antibodi bring clinic
anaptyss technolog alreadi gener mani clinic stage asset think
asset licens tesaro tsro cover
import point de-risk platform
partnership tesaro seen anab platform technolog
abl success gener antibodi sever immune-oncolog target
alreadi seen initi proof-of-concept data
demonstr extend interv vs market therapi
tesaro plan file bla msi-high tumor think readout
data esmo bla file serv import point
valid compani platform product head toward commerci
addit dose regimen everi week vs everi week keytruda
opdivo also demonstr potenc anab antibodi technolog creat longer-
although anab econom rel minor asset licens tsro mid-to-high
single-digit royalti view asset import piec valid platform
exhibit tesaro oncolog antibodi partnership
longer term think anab technolog continu gener varieti
clinic candid help diversifi stori
near-term target view checkpoint agonist auto-
although near term investor may most-focus data compani lead asset
etokimab think import aspect stori technolog
gener mani addit clinic candid well
next accord manag
compani interest checkpoint inhibitor agonist autoimmun diseas
checkpoint inhibitor turn bodi immun respons thu
use inhibit cancer tumor turn bodi immun respons
tumor signal checkpoint inhibitor
understand checkpoint agonist hard formul anab
technolog could abl
wherea checkpoint inhibitor inhibit order increas immun
respons cancer program clinic celgen cover
preclin wholli own stage focu checkpoint agon decreas
immun respons auto-immun diseas accord compani cell cell
suppress modul checkpoint inhibitor could implic across number
compani guid anoth candid move clinic
suspect agonist auto-immun diseas differ one
clinic develop celgen non-exclus collabor
explor compani technolog also saw issu patent
antibodi target ngf activin receptor type ii
know mean clinic candid think illustr
target although sure compani use antibodi technolog
could
compani mention
checkpoint agon next
oncolog seen
agon ulcer coliti
instanc gsk guid poc
data uc
targetpat receptor type iibold asset clinic stage assetssourc googl patent august
upcom asthma data key near-term stock
reason think work asthma
proof concept dupix inhibitor asthma
inhibit individu shown efficaci target
improv eosinophil asthma
extens literatur demonstr key role asthma
mani clinic preclin model shown key sustain asthmat
respons allergen instanc loss function mutat shown
offer protect asthma
activ atop dermat diseas underli
mechan similar eosinophil asthma
clinic activ atop dermat anoth allerg eosinophil condit
show activ eosinophil allerg diseas mani patient
atop dermat also asthma vice versa underli immun irregular
often
activ reduc asthmat exacerb phase peanut allergi
although data peanut allergi overli compel oral food
challeng opinion benefit seen asthma symptom patient treat
specif patient concomit allerg symptom
rhiniti pruritu uticaria asthma flare nut allergi vs placebo
larg pharma move inhibitor forward asthma stealth mode
could suggest earli clinic activ seen intern earli stage
studi compani instanc roch move phase studi
asthma move asthma studi inhibitor
good data look benefit placebo
think investor look liter improv vs placebo
think most-relev clinic comparison phase dupix data wenzel
show dupix benefit placebo high eosinophil patient
asthma phase single-dos placebo-control trial high eosinophil
first patient data get inhibitor asthma thu view
import proof concept mechan asthma atop dermat phase data
placebo arm pushback dataset trial singl dose
placebo given high eosinophil patient alreadi background steroid
long-act beta agonist
investor like make read atop dermat asthma data make
import readout stock
think current make major anab stock valuat eye
investor success asthma think help valid program
atop dermat well show role allerg diseas hand
unsuccess asthma think could creat investor doubt atop
exhibit phase asthma studi design
cantor fitzgerald research clinicaltri gov compani data
amount air blown one second measur volum liter
percent predict
forc expiratori volum one second result test includ
actual volum liter patient abl exhal one second percent predict
patient compar percentag basi healthi patient similar
demograph age sex height etc would predict key clinic measur
earli stage asthma studi indic lung function earli get read
impact rate exacerb
think most-import comparison asthma data earli
dupix data base dupix experi earlier studi think volum
percentag increas vs placebo view clinic meaning singl dose
dupix similar mechan action downstream
dupix closest commerci competitor make comparison
phase wenzel dupix show benefit vs placebo
phase studi high eosinophil patient dose dupix background steroid
laba similar phase patient specif dose
patient show increas volum basi
approxim four week dupix arm increas
placebo arm show increas thu dose dupix patient experienc
percentag increas approxim patient cohort make
rel sizabl studi
placebo activeregimensingl dose iv steroid labaplacebo steroid labaobersv timeframew estim initi top-line data might week longer term follow medic meetingsexpect compani phase asthma trial designsourc compani data cantor fitzgerald research
exhibit data phase dupix studi
key data point
compar
dose high eosinophil
 percentag
increas vs placebo
 percentag
increas
benefit vs placebo
dupix phase
anoth comparison dupix data wherein dupix show benefit
vs placebo one-to-four week dose
phase wenzel dupix also studi high eosinophil asthma patient
percentag increas directli report far find howev increas
 baselin baselin report think possibl look
addit data point although caveat math vs math
investig compani
phase dupix show increas vs placebo dose
phase dupix show improv liter high eosinophil patient
vs baselin singl dose liter month dose vs
placebo increas respect
specif singl dose dupix patient phase mean
increas volum liter vs baselin capac liter
equat increas volum four week four dose dupix
patient phase increas capac increas vs
baselin liter also look compar placebo respons
two studi ensur compar
exhibit chang baselin cantor estim
note phase studi dupix dose weekli phase
dupix dose arm everi two week everi two week
lower dose use phase studi
similar phase studi patient dupix phase studi
background long-act beta agonist laba background steroid
although effect taper laba steroid studi four week
dupix phase studi think first four week studi repres good
comparison evalu phase data
refer provid data dupix phase supplementari appendix
use calcul percentag chang
exhibit back-up calcul
supplement wenzel ford pearlman et al dupilumab persist asthma elev eosinophil
dupilumab weekli laba high dose inhal steroidsplacebo laba high dose inhal steroidsbaselin chang baelineweek singl dose chang baselin cantor week chang baselin cantor week chang baselin cantor week chang baselin cantor sourc wenzel cantor fitzgerald researchmean chang liter report wenzel chang baselin calcul mean chang baselin august
anoth measur percent predict
specif measur patient capac percentag would
predict healthi person compar characterist age sex height
dupix led increas approxim percentag point one dose
report baselin dupix placebo arm one week
one dose dupix appear around dupix arm
increas slightli placebo arm four week appear
increas dupix vs rel stabl placebo arm
overal patient popul high low eosinophil patient phase amgn/azn
cover tezepelumab anti-tslp mean increas percent
predict vs baselin week
although much longer studi look detail chang volum
basi seem increas plateau somewhat four week anoth caveat
differ patient popul high low eosinophil level patient howev given
key asset investor excit asthma space highlight comparison
patient higher eosinophil higher ige tezepelumab show greater benefit
instanc week patient high liter percentag chang
baselin high dose week vs patient low
note also high patient also exhibit higher placebo respons
phase dupilumab also show higher benefit higher eosinophil patient
found notabl high eosinophil patient benefit continu grow
time low eosinophil patient benefit seem plateau
relat anab asset think suggest believ upstream
could oper similar mechan could show increas benefit
continu dose time import keep mind single-dos readout
high eosinophil patient releas
exhibit lung function dupix percentag fev
wenzel dupilumab phase present at
note anoth depict percentag increas dupix show phase
eosinophil asthma cite benefit placebo comparison
use imag show improv efficaci time seen high
eosinophil patient popul also find imag help anoth refer
phase studi high eosinophil patient howev studi show
activ low eosinophil patient could commerci differenti
phase trial enrol patient eosinophil asthma patient
high eosinophil level clinic experi dupix know
mechan activ patient popul low eosinophil level patient
risk posit data
one risk wrong patient popul select phase studi
severe-enough patient chosen
high placebo respons think largest risk previou data saw atop
dermat singl arm data given small size studi think risk
patient placebo arm could better expect respons
safeti concern think would like know given upstream
standard target perhap could immune-rel side
effect appear
commerci mani biolog develop asthma much
atop dermat
near term howev think focu phase readout proof
mechan action
longer term howev think activ compar mani
asthma biolog order assess competit
exhibit biolog develop asthma one awar
compani data cantor fitzgerald research
despit mani player asthma space still think need better biolog
xolair sale close black box warn anaphylact shock
show efficaci roughli one everi three patient
nucala cinqair must administ physician offic
fasenra approv high eosinophil patient everi eight-week subq dose
may present improv vs prior biolog
dupix pdufa date octob think advantag dupix could
efficaci indic notabl atop dermat asthma patient often
speak doctor drawback dupix asthma advers event
hypereosinophilia seen patient
question novel novel biolog asthma space
work low eosinophil patient
patient fewer biolog option tend difficult treat
long-term safeti implic
drugcompanytargetstatu asthmaadministrationxolair omalizumab rocheigeapprov everi weeksblack box anaphylaxisnucala everi week must reconstitut administ healthcar professionalcinqair everi week infus minutesblack box anaphylaxisfasenra everi week dupix pdufa octob everi weekstezepelumabamgn/azntslpphas ongoingsubq everi receptor phase ongoingmonthli cytokin phase ongoingmonthli receptor phase ongoingeveri week receptor phase ongoingmonthli ivsourc compani data august
asthma physician much-mor familiar mechan action vs newer
earli treatment biolog halt progress mild moder asthma
becom sever
evid suggest earli inhibit atop march prevent diseas
becom sever
think dupix profil asthma look highli compel vs recent approv
specif patient eosinophil greater cell per dupix led reduct
sever asthma exacerb slightli higher seen novel
biolog agent fasenra show reduct rang depend trial cinqair
iv show reduct exacerb patient higher eosinophil
nucala show exacerb reduct howev offer standard caveat
cross-trial comparison hard make
addit think efficaci patient eosinophil level could help give
dupix usag area biolog use
although exacerb reduct patient eosinophil level
compel seen higher eosinophil patient high unmet need popul
think repres addit option patient whose asthma remain uncontrol
exhibit data comparison newli approv biolog
nejm fda
think side effect hypereosinophilia may prompt question physician
import point differenti etokimab vs dupix asthma dupix rais
eosinophil level wherea etokimab appear lower eosinophil level hit well
dupix also inhibit
dupixentcinqairnucalafasenraresult elev eosinophil patient eosinophil level screen point last ratio exacerb activ vs placebo lower asthma exacerb vs everi weekiv monthlysubq monthli administ health care settingsubq everi weekseosinophil level ratio exacerb activ vs placebo lower asthma exacerb vs labelfda labelfda labelcomparison asthma phase data new biolog august
top line would expect anoth catalyst present data
think clinic measur focu import biomark eosinophil level safeti
implic durabl respons dupix increas eosinophil level led
advers event hypereosinophilia base doctor check concern
physician look impact eosinophil well
measur feno fraction exhal nitric oxid score
atop dermat phase data key de-
risk point program
view current phase data competit atop dermat
program data need hold larger patient number
review data due durabl depth respons seen phase
data highli refractori ad popul feel comfort etokimab profil
like hold larger studi
far seen singl dose uncontrol data atop dermat
patient first top-lin novemb drive stock
compani enrol placebo control phase trial atla patient
guid top-lin data
singl dose etokimab led clinic improv similar seen
multipl dose agent atop dermat
twenty-nin day receiv one dose etokimab averag easi eczema area
sever score index reduct vs baselin across patient dose fact
one dose etokimab abl show compar efficaci seen multipl
dose competitor asset demonstr strong proof activ view bode well
data given expect respons rate increas multipl dose
key risk data small sampl size earli make strong
conclus product profil
exhibit efficaci comparison easi score atop dermat data
expect etokimab efficaci increas multipl dose
clinic experi dupix biolog show longer durat dose lead
deepen respons specif dupix inhibitor saw atop dermat
qd baricitinib singledos dupix qd chang easi score day dose vs multipl dose data agentsimprov placeboplacebo respons august
respons deepen time continu suppress contrast efficaci oral
jak inhibitor appear plateau week
dupix phase show deepen respons multipl dose similar trend expect
see multipl dose anab etokimab consid asset suppress similar
phase solo trial instanc wherea averag easi reduct
four week dose averag easi reduct increas week
etokimab upstream dupix expect similar phenomenon
exhibit efficaci dupix studi
respons etokimab highli durabl suggest potenti less-frequ dose
greater efficaci multipl dose asset abl potent suppress
despit singl administr etokimab respons day still seen
patient achiev day notabl found interest proport
patient achiev actual deepen day day
view data support monthli dose vs dupix dose everi two week
think data also demonstr potenc etokimab strong durabl day
fact efficaci still seen day also support fact multipl
dose respons etokimab like deepen respons curv
exhibit anaptysbio data atop dermat studi one dose
pushback data rescu steroid allow phase protocol
could driven respons seen patient
detail know usag steroid studi
washout period prior enrol patient allow system
rescu therapi topic steroid allow studi period ethic reason
requir pi irb
howev know mani patient receiv rescu topic steroid much
may receiv may receiv
manag character use rescu steroid studi
steroid allow patient respond patient could get
topic steroid hit thu think steroid probabl affect
respons rate non-respond elig
addit patient prior enrol inadequ control topic
steroid suggest diseas could non-respons topic steroid
seven patient system non-biolog therapi washout period
control diseas vs topic steroid allow rescu
phase atla trial studi four etokimab regimen vs placebo
specif trial enrol patient plan one placebo group four cohort
differ dose regimen
term data think investor focus comparison etokimab data
profil agent space
view think etokimab data far look competit potenti could prove
superior asset atop dermat space think possibl
target greater efficaci curb inflammatori respons simpli target
addit dose regimen monthli vs everi two week could appeal physician
howev note oral develop well upadacitinib baricitinib
import keep eye
longer term think atop dermat market grow larg space room
mani player overal think atop dermat similar psoriasi rheumatoid arthriti
space room mani product chronic condit larg preval
treat moderate-to-sever atop dermat patient us think largest commerci
barrier get physician specif dermatologist comfort use biolog
think multipl pharmaceut player space encourag uptak build
awar help grow market size overal long term
commerci risk
larg establish commerci player competit
potenti oral approv
exhibit data comparison atop dermat data
drugdosingnstudy/sourcechang easi score easi score weekseasi weekseasi weekli weekli topic weekli subq standard regimen topic iv mg/kg iv day percentag body-surfac area beck et al nejm eaaci present may aad morphosi press releas feb phase data present phase phase atop dermat dataphas august
patient data two indic make
next key valu driver share
think help diversifi beyond help
valid compani platform technolog
receptor inhibitor implic sever sever form
initi studi two indic gener pustular psoriasi gpp
palmoplantar pustulosi ppp
gpp rare sever potenti life-threaten dermatolog condit wherea ppp
difficult-to-treat varieti psoriasi occur primarili hand feet
exhibit breakdown psoriasi type
preval ppp much larger gpp also much-less sever
diseas howev check think ppp poorli control exist
biolog underdiagnos could potenti larg market opportun
think ultim ppp much-larg market opportun gpp howev
two diseas similar underli biolog show posit data
gpp think investor make read potenti success ppp
howev given vastli differ preval two diseas success
gpp think compani could charg rare-diseas type price enabl anb-
still market opportun way reach market
dermatolog condit contrast success ppp gpp
psoriasisplaqu psoriasi case guttat psoriasi case pustular case gener pustular psoriasi gpp palmoplantar pustulosi ppp local case invers case
exhibit compar gpp ppp diseas
data gpp open label trial first patient data see
success think investor begin give credit gpp ppp condit
latter like much-larg market opportun compani plan start
patient trial ppp data guid
note boehring ingelheim cover also inhibitor
develop ppp gpp bi unabl find much
asset except bi studi ppp gpp phase uc asset
patient phase studi asset ppp complet enrol march
primari endpoint pppasi palmoplantar pustular psoriasi area sever index
week treatment accord clinicaltri gov studi complet juli
although know result made public
interest takeaway expert check
surpris physician thought much-great unmet need ppp
gpp sever consult spoke note ppp highli recalcitr
diseas respond well tradit biolog also report lot
ppp patient suspect underdiagnos code gener
psoriasi patient receiv reimburs biolog especi
case although patient ppp also underli plaqu
psoriasi debat literatur among physician whether ppp
form psoriasi whether diseas right physician spoke
gener pustular psoriasispalmoplantar pustulosissymptoms-larg area skin red inflammed-pus-fil blister across body-fever-fatigue-muscl weakness-organ inflamm cholangitis-pus-fil blister similar gpp hand feet-blist often harden turn dark scale patch hand feet-itch burn hand feetdiagnosisbas physic exam physic examfung cultur rule fungal infect vs pppagestyp adultstyp adultsrisk factorsmed steroidsinfectionspregnancymost patient smokersmed tnf inhibitorsinfectionscomplicationssystem infectionssepsiscan fatal controlledqu life impactstreatmentpotenti hospit support caresystem immune-suppressantstop immune-suppressantssystem immune-suppressantsu
actual report treat select case ppp psoriasi present
sever physician spoke also thought mechan could
implic psoriasi broadli gpp ppp indic could
present speedier pathway market note success gpp
ppp would want see explor potenti usag type refractori
exhibit overview gpp/ppp diseas involv
could speedi path market
interestingli think gpp could first wholli own
product could reach market even etokimab
potenti speedi pathway gpp
gpp rare form psoriasi fatal
gpp rare form pustular psoriasi character red sensit skin pus-fil
blister pustul most-sever form intern organ becom inflam lead
diseas becom fatal control repeat flare-up tend entail fever system rash
think inhibitor high likelihood success gpp
genet valid target gpp
directli target overproduc characterist gpp think
mechanist target high probabl clinic success gpp specif gpp
establish link overexpress cytokin although mani case gpp
direct genet caus mani case document stem sole mutat
caus overexpress demonstr clear link overexpress
develop gpp
approv therapeut gpp
current gpp manag cyclosporin steroid immune-suppress
methotrex notabl anti-tnf therapi known induc case gpp treatment
use first-lin agent gpp inhibitor howev shown efficaci
spoken doctor use label
think gpp alon could market opportun also approv
base nation claim data anapti found gpp patient us would expect orphan-
like price given sever gpp diseas cours also work ppp
preval us would expect much-larg product
smaller proport sale come gpp would expect product price much
work gpp increas confid work ppp
larger opportun two ppp palmoplantar pustulosi thu think proof
concept gpp import get investor pay attent potenti opportun
reason think work gpp
genet valid target mutat caus gpp
upregul gpp patient gpp pustul
clinic data show efficaci anakinra inhibitor downstream
overview gpp patholog genet link gpp mutat key
reason could work gpp
gpp genet origin defici receptor antagonist
mani patient gpp mutat gene receptor antagonist ra
anti-inflammatori cytokin modul level mutat gene encod
found result gpp wide express skin
typic mediat level patient gpp lower level
antagonist lead enhanc inflammatori respons
patient ditra defici interleukin thirty-six receptor antagonist lack antagonist
lead higher level signal lead increas level cytokin
 downstream inflammatori cascad
gpp occur patient without prior tradit psoriasi
gpp occur patient prior present psoriasi vulgari plaqu psoriasi
patient diseas first present gpp
commonli case gpp without tradit psoriasi genet variant
case patient gpp without tradit psoriasi usual occur patient homozyg
heterozyg mutat gene report sugiura patient
develop gpp prior histori typic psoriasi usual mutat
debat scientif commun whether group patient
classifi differ subtyp gpp whether similar underli patholog
specif discuss whether patient mutat patient
prior psoriasi differ subtyp underli caus gpp diseas thu respond
differ treatment know answer think import look
evalu subgroup data dose gpp patient
regardless import view presenc mutat caus
diseas demonstr strong link gpp patholog patient without
underli skin inflammatori process suscept develop diseas
upregul patient without mutat still demonstr elev
current treatment gpp base manag acut flare-up
think need better mainten therapi prevent
speak physician learn exist immune-suppress reason efficaci
manag acut sever flare-up physician spoke report use strong immune-
suppress agent initi discontinu treatment flare-up resolv due
safeti concern agent patient respond physician tri varieti
differ immune-suppress agent physician spoke note abl control
flare-up patient gpp
howev think strong need agent also use mainten
set patient whose flare-up easili control
physician report switch anti-tnf use high intens immune-suppress
flare-up order prevent flare-up gpp indic anti-
tnf effect mainten agent
goal treatment gpp get immun reaction flare-up control
end varieti immune-suppress use vari efficaci
lot data efficaci agent use typic gpp acitretin
methotrex cyclosporin check physician medic effect
initi get diseas control patient may experi addit flare-up
especi case mani therapi acitretin recommend long-term
usag due safeti concern
physician spoke use label inhibitor inhibitor
limit data efficaci agent agent formal approv
condit
exhibit treatment paradigm gpp
drawback current avail agent support need better treatment gpp
especi treatment safe chronic use vs simpli use acut set
acitretin effect use commonli signific safeti concern limit
chronic usag guidelin recommend first agent use treat gpp studi
shown effect control gpp flare-up howev use drug
limit refractori type sever psoriasi caus sever birth defect
liver damag thu chronic usag ideal patient typic treat
acitretin flare-up wean flare control leav
patient risk futur flare-up
cyclosporin effect safeti concern limit chronic usag cyclosporin tie
increas risk skin malign caus system hypertens
methotrex effect safeti concern specif birth defect liver
toxicity/fibrosis/cirrhosi prolong use acut alt/ast abnorm increas
risk malign document methotrex onset activ
also slower vs cyslosporin acitretin
tnf inhibitor high rate infect seen gpp patient treat
anti-tnf gpp patient alreadi high risk infect physician seem
prefer use remicad humira enbrel tnf treat
gpp studi avail data shown remicad shorter time
remiss vs humira enbrel gpp patient tnf show efficaci control
gpp flare mani patient doctor spoke mention tnf work
effect control gpp patient howev view drug
better efficacy/safeti combin would meaning uptak infect
risk associ tnf specif gpp patient high risk infect
begin
medic board nation psoriasi foundat guidelin kalb lineacitreinclyclosporinmethotrexateinfliximab remicad second cosentyx taltz tnf humira enbrel puva combin topic
exhibit summar effiaci safeti tnf inhibitor gpp
think like preval gpp underestim industri literatur
could find mani paper on-line discuss preval gpp howev found
preval vari wide treatment paradigm rel similar
difficult-to-treat skin condit extens usag immune-suppress diseas
control like littl need differenti diagnosi gpp
exhibit preval gpp literatur
everi physician spoke seen case gpp case compar typic
plaqu psoriasi even ppp patient expect
preval estimateimpli us per per per per look us nation claim datasourc compani data sourc cite abovepreval estim gpp august
speak doctor got sens gpp rare doctor spoke
seen hand case case diseas present clinic practic everi month
major academ center hand patient care condit
sever on-going recent complet studi biolog gpp japan
limit detail studi potenti data
unsur statu phase trial albeit small ran adalimumab
risankizumab gpp patient japan cover also current run trial
guselkumab japan gpp patient
exhibit studi way gpp could find
compani data clinicaltri gov
phase studi open label studi monthli dose
primari endpoint efficaci base cgi clinician global impress scale
cgi assess physician patient classifi five categori much
improv much improv minim improv chang worsen
patient consid clinic respons physician grade much
improv much improv minim improv primari endpoint studi
determin proport patient clinic respons base grade scale
exhibit studi design gpp
targetdrugcompanyphasestudi namenprimari complet multicent open-label studi adalimumab japanes subject gener pustular actual date per phase random open-label studi assess efficaci safeti differ dose regimen risankizumab administ subcutan japanes subject gener pustular psoriasi erythroderm actual date per phase multicent open-label studi evalu efficaci safeti guselkumab treatment subject gener pustular psoriasi erythroderm per singl arm multipl dose studi assess efficaci safeti subject gener pustular data guid clinicaltri gov compani data
stock perspect think investor mostli care proof activ vs
superior therapi gpp sinc limit avail comparison
manag note on-going gpp studi involv highli sever patient thu think
even small proport transit chronic usag toxic immune-suppress
exampl retinoid cyclosporin would meaning data
think success gpp demonstr divers pipelin anoth clinic
also think activ gpp import read-through potenti efficaci
much-larg indic ppp
limit detail clinic studi done gpp make difficult make
comparison small studi primarili done japan
studi found gpp speak manag
think good comparison patient much-mild condit
enrol studi specif enrol patient baselin
jda score higher denot highli sever patient think comparison
valu howev think investor want see comparison refer
exhibit gpp studi inhibitor
subqno placeboopen weeksprimari endpointproport subject achiev clinic respons clinic global impress cgi scaleincid advers event week endpointsjapanes dermatolog associ sever mjda dermatolog life qualiti instrument dlqi gpp studi remiss improv patientsyamasaki achiev spga week success measur cgi achiev patient week global impress improv static physician global assessmentgpp studi could find august
compani data clinicaltri gov
gpp
think ppp could market opportun phase data guid
could key valu driver share
think littl credit given ppp think
success could signific market opportun ppp
doctor spoke report ppp highli preval condit practic
larg proport ppp patient difficult treat fail mani
ppp pus-fil blister hand feet often harden scale
pustul pu fill blister seen gpp also seen ppp pustul typic form
hand feet itchi pain inhibit day-to-day activ although
condit life-threaten pustul often dri thicken becom harden scale around
skin result confus fungal infect similar gpp anti-tnf treatment
actual trigger flare-up vs help control flare-up
larg preval ppp highli preval form psoriasi estim
patient us
unmet need limit activ exist biolog speak sever
dermatologist learn ppp remain key unmet need practic
diseas often respond tradit immune-suppress off-label biolog
 anti-tnf think good thing bad thing
one hand unmet need high highli preval popul
hand could recalcitr patient popul complic biolog
highli disrupt diseas qualiti life blister occur hand feet
diseas highli disrupt patient qualiti life pain walk pain use
hand although diseas sever gpp life-threaten
check suggest ppp patient persist seek addit therapi
disrupt blister hand feet
initi patient data anapti plan initi multi-dos placebo
control trial ppp top-lin data guid
reason could work ppp
express higher level ppp pustul biopsi vs suggest
recent literatur shown upregul plaqu psoriasi pustular psoriasi
gener broader psoriat disord ppp
preclin model ppp psoriasi gener show efficaci
mutat found gpp patient also seen ppp patient albeit
also link broader plaqu psoriasi indic also point mani
physician spoke mention
psoriat lesion found higher level gene express
express found highli correl level
tnf-alpha target know implic ppp psoriasi gener
receptor commonli found skin
major plaqu psoriasi patient elev ratio agonist/receptor
wherea minor ra crohn patient elev suggest uniqu
inflammatori involv skin condit although note bi studi
uc
exhibit ppp studi could inconclus result exist biolog
compani data clinicaltri gov
patient othersbissonnett statist signific differ vs placebobissonnett signific improvemetn vs placeboterui ppp studi could find
present ppp market estim think market potenti could peak
addit valuat scenario base model work
etokimab bull scenario increas probabl etokimab
dcf increas
increas probabl success etokimab asthma atop dermat
indic vs respect base case dcf increas
upsid base case model probabl etokimab asthma
ad dcf increas higher current market price
longer term etokimab success indic model
asthma atop dermat dcf increas increas vs
exhibit etokimab bull scenario greater confid
etokimab super bear downsid risk base case etokimab
unsuccess
success etokimab full valu fv would depend
much credit give etokimab complet fail see data anb-
although think outright failur highli unlik would expect share trade
closer cash tsro collabor revenu would
downsid vs base case
also consid scenario success clinic develop
leav etokimab estim unchang
bull scenario credit gpp ppp could worth
overal valuat would etokimab assumpt unchang
credit gpp ppp would worth overal dcf would
investor get increment comfort etokimab ad asthma
base case see impress sign activ gpp ppp think could provid
share meaning upsid current level probabl ppp
gpp specif base dcf credit gpp ppp could worth
could worth
think offer import piec diversif case etokimab data disappoint
investor becom bearish market opportun competit landscap
exhibit bull scenario
credit
think program
could worth
success
bull scenario etokimab readout success
think share could end year high base dcf
fundament basi dcf assign credit etokimab credit anb-
gpp ppp dcf would worth solid data etokimab
asthma readout well phase atla atop dermat trial
think investor becom comfort asset modal assign credit
similarli strong data gpp ppp studi think investor begin pay
attent give credit asset well super bull scenario success etokimab
gpp ppp dcf valuat share would
exhibit bull scenario
clinic readout success think becom topic convers
small compani limit commerci infrastructur current although think
could build commerci capabl think either clinic asset show
strong efficaci investor could begin view compani valuat perspect
much valu could add strateg parti vs stand-alone compani
exhibit scenario analysi base model
clinic asset de-risk see meaning upsid peak sale multipl
assign potenti product sale also think clinic asset de-risk
import stock driver level
probabl success unadjust sale adjust atop market peanut sale sale multipl cantor equiti research year launch august
worst case scenario etokimab fail think share could trade low
cash npv tsro mileston although base case assumpt
suggest dcf would
rule outsiz loss share point either especi
recogn still lot downsid potenti etokimab especi upcom asthma
data although think complet failur etokimab unlik base
current know asset
comfort downsid risk etokimab ahead come asthma readout
see downsid protect readout beyond
key reason uncomfort potenti downsid diversif forese
potenti success
etokimab fail show promis success think share
could trade time
success etokimab program dcf would without
lower expens success alon dcf share would
said think investor may need see sever stage readout
becom comfort asset
exhibit scenario analysi suc
exampl etokimab total failur see strong proof-of-concept data
gpp ppp think share could recov time valu
valuat risk
price target overweight rate base probabl adjust dcf extend
estim assum discount rate line anab small-cap peer assign
share termin valu growth rate line peer
deriv revenu estim assign probabl success etokimab atop
dermat probabl success etokimab asthma probabl success
etokimab crswnp peak probabl adjust sale indic result
ad asthma crswnp respect assign
probabl success gpp ppp respect probabl adjust sale estim
includ model gpp ppp
base net work growth termin market sale per sensit assum sale market august
clinic trial enrol speed may slower compani forecast result
delay clinic trial readout timelin would put revenu estim risk
either program due delay develop
lack efficaci etokimab atop dermat asthma crswnp would put
revenu estim risk either program due delay develop
safeti issu aris etokimab would put revenu estim risk
either program due delay develop
lack efficaci safeti concern either gpp ppp would
put revenu estim risk either program due delay develop
better-than-expect data commerci competitor asthma atop dermat gpp
ppp crswnp could result much-smal market opportun forecast
includ key manag biographi websit refer
hamza suria appoint ceo sinc led transform
earli platform technolog focu develop robust antibodi product pipelin across key
therapeut area prior mr suria maxygen respons
partner allianc manag next-gener protein therapeut oncolog support
care hematolog autoimmun includ partnership roch sanofi-aventi bayer
astella mr suria hold sc biochemistri kalamazoo colleg immunolog
univers western ontario execut richard ivey school
busi mr suria graduat mercersburg academi
marco londei join bristol-my squibb bm
therapeut area head immunosci respons earli clinic translat research
portfolio immune-rel therapeut prior bm dr londei global head
autoimmun translat medicin novarti translat scienc offic genom
institut novarti research foundat led design execut earli
stage clinic studi novarti bm includ develop secukinumab canakinumab
sever biolog therapi immune-medi inflammatori diseas dr londei receiv
faculti medicin univers bologna conduct post-doctor
studi tumor immunolog london uk key member team pioneer
develop anti-tnf therapi kennedi institut rheumatolog kir faculti
medicin imperi colleg london dr londei professor faculti medicin imperi
colleg london professor autoimmun gastroenterolog consult univers
colleg london prior join novarti wide recogn world-class contributor
inflamm publish peer-review paper field autoimmun self-
recognit immun modulatori checkpoint
domin piscitelli join chief offic januari
year industri experi experi commerci product launch xtandi
tarceva market partnership in-licens transact acquisit debt equiti
financ prior join mr piscitelli vice presid financ strategi
investor relat mediv inc play key role acquisit
mr piscitelli serv senior director collabor oper financ
astella pharmaceut mr piscitelli serv variou role increas
respons culmin vice presid treasuri manag financ osi
pharmaceut play signific role acquisit astella pharmaceut mr
piscitelli hold bachelor degre account master degre financ certifi
cantor fitzgerald statement million except per share adj product product product product oper expens profit/ loss non-gaap expens net paid benefit tax income/ loss weight average share weight average share basic dilut basic dilut
valuat assumptionsprob success unadjust sale adjust salesdcf atop market peanut sale sale multipl cantor equiti research year launch revenu salesatop adjust salesatop probabl adjust probabl unadjust sale adjust sale
cantor fitzgerald sale sale adultsatop dermat preval moder treat moder steroid topic jak uncontrol mod-sever mod-sever total diagnos biologics/jak price effect atop derm sale us
anaptysbiocantor fitzgerald build diagnos moder biolog penetration- price discount effect
compani report cantor fitzgerald research
cantor fitzgerald balanc sheet million except per share asset cash tax incent expens current current equip long term equitycurr liabil account payabl current current current payabl net current paid comprehens stockhold equiti liabil convert prefer stock stockhold equiti
compani report cantor fitzgerald research
cantor fitzgerald statement million except per share flow oper activ net reconcil net loss net cash use oper activ depreci fair valu liabil prefer stock interest dispos properti oper asset liabil receiv collabor tax incent expens payabl tax cash use oper flow invest activ acquisit matur properti cash use invest flow financ activ proce public offer net underwrit issuanc common stock upon exercis stock issuanc prefer stock net issuanc cash provid financ increas decreas cash cash equival restrict cash equival restrict cash begin cash equival restrict cash end august
